U.S. patent application number 15/431654 was filed with the patent office on 2017-06-08 for carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b.
The applicant listed for this patent is Janssen Sciences Ireland UC. Invention is credited to Geerwin Yvonne Paul HACHE, Bart Rudolf Romanie KESTELEYN, Pierre Jean-Marie Bernard RABOISSON, Koen VANDYCK.
Application Number | 20170158634 15/431654 |
Document ID | / |
Family ID | 49447486 |
Filed Date | 2017-06-08 |
United States Patent
Application |
20170158634 |
Kind Code |
A1 |
VANDYCK; Koen ; et
al. |
June 8, 2017 |
CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE
TREATMENT OF HEPATITIS B
Abstract
Inhibitors of HBV replication of formula (I) ##STR00001##
including stereochemically isomeric forms, and salts, hydrates,
solvates thereof, wherein X, R.sup.1 to R.sup.7 have the meaning as
defined herein. The present invention also relates to processes for
preparing said compounds, pharmaceutical compositions containing
them and their use, alone or in combination with other HBV
inhibitors, in HBV therapy.
Inventors: |
VANDYCK; Koen;
(Paal-Beringen, BE) ; HACHE; Geerwin Yvonne Paul;
(Kapellen, BE) ; KESTELEYN; Bart Rudolf Romanie;
(Berlare, BE) ; RABOISSON; Pierre Jean-Marie Bernard;
(Rosieres, BE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Janssen Sciences Ireland UC |
Co Cork |
|
IE |
|
|
Family ID: |
49447486 |
Appl. No.: |
15/431654 |
Filed: |
February 13, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15031493 |
Apr 22, 2016 |
9567299 |
|
|
PCT/EP2014/072690 |
Oct 22, 2014 |
|
|
|
15431654 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 43/00 20180101;
C07D 207/09 20130101; A61K 31/40 20130101; A61K 31/4025 20130101;
C07D 207/16 20130101; C07D 211/60 20130101; A61P 1/16 20180101;
A61P 31/20 20180101; C07D 405/12 20130101; C07D 211/34 20130101;
A61K 31/445 20130101; A61K 45/06 20130101 |
International
Class: |
C07D 207/16 20060101
C07D207/16; C07D 211/60 20060101 C07D211/60; A61K 45/06 20060101
A61K045/06; A61K 31/4025 20060101 A61K031/4025; A61K 31/445
20060101 A61K031/445; C07D 405/12 20060101 C07D405/12; A61K 31/40
20060101 A61K031/40 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 23, 2013 |
EP |
13189880.1 |
Claims
1. A compound of Formula (I) ##STR00055## or a stereoisomer or
tautomeric form thereof, wherein: ##STR00056## represents
##STR00057## each of Ra, Rb, Rc, Rd, Re, Rf and Rg are
independently selected from the group consisting of Hydrogen and
methyl; Rh is Hydrogen; Ri is Hydrogen; R.sup.1, R.sup.2and R.sup.3
are independently selected from the group consisting of Hydrogen,
Fluoro, Chloro, Bromo, --CHF.sub.2, --CH.sub.2F, --CF.sub.3, --CN
and methyl; R.sup.6 is selected from the group consisting of
C.sub.1-C.sub.6alkyl and a 3-7 membered saturated ring optionally
containing one or more heteroatoms each independently selected from
the group consisting of 0, S and N, such C.sub.i-C.sub.6alkyl or
3-7 membered saturated ring optionally substituted with one or more
substituents selected from the group consisting of Fluoro,
C.sub.1-C.sub.3alkyl optionally substituted with one or more
Fluoro, CN, OH; R.sup.7 represents hydrogen; or a pharmaceutically
acceptable salt or a solvate thereof.
2. A compound of according to claim 1 with Formula (II)
##STR00058## or a stereoisomer or tautomeric form thereof, wherein:
n indicates an integer of 1 or 2; R.sup.1, R.sup.2and R.sup.3 are
independently selected from the group consisting of Hydrogen,
Fluoro, Chloro, Bromo, --CHF.sub.2, --CH.sub.2F, --CF.sub.3, --CN
and methyl; R.sup.4 and R.sup.5 are independently selected from
Hydrogen or methyl; R.sup.6 is selected from the group consisting
of C.sub.1-C.sub.6alkyl and a 3-7 membered saturated ring
optionally containing one or more heteroatoms each independently
selected from the group consisting of 0, S and N, such
C.sub.i-C.sub.6alkyl or 3-7 membered saturated ring optionally
substituted with one or more substituents selected from the group
consisting of Fluoro, C.sub.1-C.sub.3alkyl optionally substituted
with one or more Fluoro, --CN, OH; R.sup.7 represents hydrogen; or
a pharmaceutically acceptable salt or a solvate thereof
3. A compound according to claim 1 or 2, wherein R.sup.1 is
selected from hydrogen, Fluoro, Chloro, --CHF.sub.2, --CN,
--CF.sub.3 or methyl.
4. A compound according to anyone of claims 1 to 3 wherein at least
two of R.sup.1, R.sup.2 and R.sup.3 are Fluoro, Chloro or
Bromo.
5. A compound according to any one of the previous claims wherein
R.sup.4 is methyl.
6. A compound according to any one of the previous claims wherein
R.sup.6 contains a 3-7 membered saturated ring optionally
containing one oxygen, such 3-7 membered saturated ring optionally
substituted with methyl.
7. A compound according to any one of the previous claims wherein
R.sup.6 is a 4 or 5 membered saturated ring containing one oxygen,
such 4 or 5 membered saturated ring optionally substituted with
methyl.
8. A compound according to any one of claims 1 to 5, wherein
R.sup.6 is a branched C.sub.1-C.sub.6alkyl optionally substituted
with one or more Fluoro.
9. A compound according to any one of the previous claims with
Formula (III) ##STR00059## wherein R.sup.1 is not Hydrogen.
10. A compound according to any one of the previous claims, wherein
the stereochemical configuration of atom (*) is as follows
##STR00060##
11. A compound according to any one of the previous claims for use
in the prevention or treatment of an HBV infection in a mammal.
12. A pharmaceutical composition comprising a compound according to
any of claims 1 to 10, and a pharmaceutically acceptable
carrier.
13. A compound according to any one of claims 1 to 10, or a
pharmaceutical composition according to claim 12 in combination
with at least one other anti-HBV agent.
Description
BACKGROUND ART
[0001] The Hepatitis B virus (HBV) is an enveloped, partially
double-stranded DNA (dsDNA) virus of the Hepadnavirus family
(Hepadnaviridae). Its genome contains 4 overlapping reading frames:
the precore/core gene; the polymerase gene; the L, M, and S genes,
which encode for the 3 envelope proteins; and the X gene.
[0002] Upon infection, the partially double-stranded DNA genome
(the relaxed circular DNA; rcDNA) is converted to a covalently
closed circular DNA (cccDNA) in the nucleus of the host cell and
the viral mRNAs are transcribed. Once encapsidated, the pregenomic
RNA (pgRNA), which also codes for core protein and Pol, serves as
the template for reverse transcription, which regenerates the
partially dsDNA genome (rcDNA) in the nucleocapsid.
[0003] HBV has caused epidemics in parts of Asia and Africa, and it
is endemic in China. HBV has infected approximately 2 billion
people worldwide of which approximately 350 million people have
developed chronic infections. The virus causes the disease
hepatitis B and chronic infection is correlated with a strongly
increased risk for the development cirrhosis and hepatocellular
carcinoma.
[0004] Transmission of hepatitis B virus results from exposure to
infectious blood or body fluids, while viral DNA has been detected
in the saliva, tears, and urine of chronic carriers with high titer
DNA in serum.
[0005] An effective and well-tolerated vaccine exists, but direct
treatment options are currently limited to interferon and the
following antivirals; tenofovir, lamivudine, adefovir, entecavir
and telbivudine.
[0006] In addition, heteroaryldihydropyrimidines (HAPs) were
identified as a class of HBV inhibitors in tissue culture and
animal models (Weber et al., Antiviral Res. 54: 69-78).
[0007] WO2013/006394, published on Jan. 10, 2013, relates to
Sulphamoyl-arylamides active against HBV.
[0008] WO/2013/096744, published on Jun. 26, 2013 relates to
compounds active against HBV.
[0009] Amongst the problems which HBV direct antivirals may
encounter are toxicity, mutagenicity, lack of selectivity, poor
efficacy, poor bioavailability, and difficulty of synthesis.
[0010] There is a need for additional HBV inhibitors that may
overcome at least one of these disadvantages or that have
additional advantages such as increased potency or an increased
safety window.
DESCRIPTION OF THE INVENTION
[0011] The present invention relates to a compound of Formula
(I)
##STR00002##
[0012] or a stereoisomer or tautomeric form thereof, wherein:
##STR00003##
[0013] represents
##STR00004## [0014] each of Ra, Rb, Rc, Rd, Re, Rf and Rg are
independently selected from the group consisting of Hydrogen and
methyl; [0015] Rh is Hydrogen; [0016] Ri is Hydrogen; [0017]
R.sup.1, R.sup.2and R.sup.3 are independently selected from the
group consisting of Hydrogen, Fluoro, Chloro, Bromo, --CHF.sub.2,
--CH.sub.2F, --CF.sub.3, --CN and methyl; [0018] R.sup.6 is
selected from the group consisting of C.sub.1-C.sub.6alkyl and a
3-7 membered saturated ring optionally containing one or more
heteroatoms each independently selected from the group consisting
of O, S and N, such C.sub.1-C.sub.6alkyl or 3-7 membered saturated
ring optionally substituted with one or more substituents selected
from the group consisting of Fluoro, C.sub.1-C.sub.3alkyl
optionally substituted with one or more Fluoro, --CN, OH; [0019]
R.sup.7 represents hydrogen;
[0020] or a pharmaceutically acceptable salt or a solvate
thereof.
[0021] The invention further relates to a pharmaceutical
composition comprising a compound of Formula (I), and a
pharmaceutically acceptable carrier.
[0022] The invention also relates to the compounds of formula (I)
for use as a medicament, preferably for use in the prevention or
treatment of an HBV infection in a mammal.
[0023] In a further aspect, the invention relates to a combination
of a compound of formula (I), and another HBV inhibitor.
DEFINITIONS
[0024] The term "C.sub.1-.sub.3alkyl" or C.sub.1-C.sub.4alkyl as a
group or part of a group refers to a hydrocarbyl radical of Formula
C.sub.nH.sub.2n+1 wherein n is a number ranging from 1 to 3. In
case C.sub.1-3alkyl is coupled to a further radical, it refers to a
Formula C.sub.nH.sub.2n. C.sub.1-3alkyl groups comprise from 1 to 3
carbon atoms, more preferably 1 to 2 carbon atoms. C.sub.1-3alkyl
includes all linear, or branched alkyl groups with between 1 and 3
carbon atoms, and thus includes such as for example methyl, ethyl,
n-propyl, and i-propyl.
[0025] C.sub.1-4alkyl as a group or part of a group defines
straight or branched chain saturated hydrocarbon radicals having
from 1 to 4 carbon atoms such as the group defined for
C.sub.1-3alkyl and butyl and the like.
[0026] C.sub.1-6alkyl, C.sub.2-6alkyl and C.sub.3-6alkyl as a group
or part of a group defines straight or branched chain saturated
hydrocarbon radicals having from 1 to 6 carbon atoms, or from 2 to
6 carbon atoms or from 3 to 6 carbon atoms such as the groups
defined for C.sub.1-4alkyl and pentyl, hexyl, 2-methylbutyl and the
like.
[0027] As used herein, the term "3-7 membered saturated ring" means
saturated cyclic hydrocarbon with 3, 4, 5, 6 or 7 carbon atoms and
is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and
cycloheptyl or C.sub.3-, C.sub.4-, C.sub.5-, C.sub.6- or C.sub.7--
cycloalkyl .
[0028] Such saturated ring optionally contains one or more
heteroatoms, such that at least one carbon atom is replaced by a
heteroatom selected from N, O and S, in particular from N and O.
Examples include oxetane, tetrahydro-2H-pyranyl, piperidinyl,
tetrahydrofuranyl, morpholinyl, thiolane 1,1-dioxide and
pyrrolidinyl. Preferred are saturated cyclic hydrocarbon with 3 or
4 carbon atoms and 1 oxygen atom. Examples include oxetane, and
tetrahydrofuranyl.
[0029] The term halo and halogen are generic to Fluoro, Chloro,
Bromo or lodo. Preferred halogens are Fluoro and Chloro.
[0030] It should also be noted that the radical positions on any
molecular moiety used in the definitions may be anywhere on such
moiety as long as it is chemically stable. For instance pyridyl
includes 2-pyridyl, 3-pyridyl and 4-pyridyl; pentyl includes
1-pentyl, 2-pentyl and 3-pentyl.
[0031] A bond indicated with indicates the attachment of the
indicated fragment to the main structure of the molecule.
[0032] Positions indicated on phenyl (e.g. ortho, meta and/or para)
are indicated relative to the bond connecting the phenyl to the
main structure. An example with regard to the position of R.sup.1,
any location is indicated relative to the nitrogen (*) connected to
the main structure:
##STR00005##
[0033] When any variable (e.g. halogen or C.sub.1-4alkyl) occurs
more than one time in any constituent, each definition is
independent.
[0034] For therapeutic use, the salts of the compounds of formula
(I) are those wherein the counter ion is pharmaceutically or
physiologically acceptable. However, salts having a
pharmaceutically unacceptable counter ion may also find use, for
example, in the preparation or purification of a pharmaceutically
acceptable compound of formula (I). All salts, whether
pharmaceutically acceptable or not are included within the ambit of
the present invention.
[0035] The pharmaceutically acceptable or physiologically tolerable
addition salt forms which the compounds of the present invention
are able to form can conveniently be prepared using the appropriate
acids, such as, for example, inorganic acids such as hydrohalic
acids, e.g. hydrochloric or hydrobromic acid; sulfuric;
hemisulphuric, nitric; phosphoric and the like acids; or organic
acids such as, for example, acetic, aspartic, dodecylsulphuric,
heptanoic, hexanoic, nicotinic, propanoic, hydroxyacetic, lactic,
pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic,
tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic,
p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic
and the like acids.
[0036] Conversely said acid addition salt forms can be converted by
treatment with an appropriate base into the free base form.
[0037] The term "salts" also comprises the hydrates and the solvent
addition forms that the compounds of the present invention are able
to form. Examples of such forms are e.g. hydrates, alcoholates and
the like.
[0038] The present compounds may also exist in their tautomeric
forms. For example, tautomeric forms of amide (--C(.dbd.O)--NH--)
groups are iminoalcohols (--C(OH).dbd.N--). Tautomeric forms,
although not explicitly indicated in the structural formulae
represented herein, are intended to be included within the scope of
the present invention.
[0039] The term stereochemically isomeric forms of compounds of the
present invention, as used hereinbefore, defines all possible
compounds made up of the same atoms bonded by the same sequence of
bonds but having different three-dimensional structures which are
not interchangeable, which the compounds of the present invention
may possess. Unless otherwise mentioned or indicated, the chemical
designation of a compound encompasses the mixture of all possible
stereochemically isomeric forms which said compound may possess.
Said mixture may contain all diastereomers and/or enantiomers of
the basic molecular structure of said compound. All
stereochemically isomeric forms of the compounds of the present
invention both in pure form or in admixture with each other are
intended to be embraced within the scope of the present
invention.
[0040] Pure stereoisomeric forms of the compounds and intermediates
as mentioned herein are defined as isomers substantially free of
other enantiomeric or diastereomeric forms of the same basic
molecular structure of said compounds or intermediates. In
particular, the term `stereoisomerically pure` concerns compounds
or intermediates having a stereoisomeric excess of at least 80% (i.
e. minimum 90% of one isomer and maximum 10% of the other possible
isomers) up to a stereoisomeric excess of 100% (i.e. 100% of one
isomer and none of the other), more in particular, compounds or
intermediates having a stereoisomeric excess of 90% up to 100%,
even more in particular having a stereoisomeric excess of 94% up to
100% and most in particular having a stereoisomeric excess of 97%
up to 100%. The terms `enantiomerically pure` and
`diastereomerically pure` should be understood in a similar way,
but then having regard to the enantiomeric excess, respectively the
diastereomeric excess of the mixture in question.
[0041] Pure stereoisomeric forms of the compounds and intermediates
of this invention may be obtained by the application of art-known
procedures. For instance, enantiomers may be separated from each
other by the selective crystallization of their diastereomeric
salts with optically active acids or bases. Examples thereof are
tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and
camphosulfonic acid. Alternatively, enantiomers may be separated by
chromatographic techniques using chiral stationary phases. Said
pure stereochemically isomeric forms may also be derived from the
corresponding pure stereochemically isomeric forms of the
appropriate starting materials, provided that the reaction occurs
stereospecifically. Preferably, if a specific stereoisomer is
desired, said compound will be synthesized by stereospecific
methods of preparation. These methods will advantageously employ
enantiomerically pure starting materials.
[0042] The diastereomeric forms of formula (I) can be obtained
separately by conventional methods. Appropriate physical separation
methods that may advantageously be employed are, for example,
selective crystallization and chromatography, e.g. column
chromatography.
[0043] The present invention is also intended to include all
isotopes of atoms occurring on the present compounds. Isotopes
include those atoms having the same atomic number but different
mass numbers. By way of general example and without limitation,
isotopes of Hydrogen include tritium and deuterium. Isotopes of
carbon include C-13 and C-14.
DETAILED DESCRIPTION OF THE INVENTION
[0044] Whenever used hereinafter, the term "compounds of formula
(I)",
##STR00006##
[0045] or, "the present compounds" or similar term is meant to
include the compounds of general formula (I), (II), (III) salts,
stereoisomeric forms and racemic mixtures or any subgroups
thereof.
[0046] In a first aspect, the invention provides compound of
Formula (I)
##STR00007##
[0047] or a stereoisomer or tautomeric form thereof, wherein:
##STR00008##
[0048] represents
##STR00009## [0049] each of Ra, Rb, Rc, Rd, Re, Rf and Rg are
independently selected from the group consisting of Hydrogen and
methyl; [0050] Rh is Hydrogen; [0051] Ri is Hydrogen; [0052]
R.sup.1, R.sup.2and R.sup.3 are independently selected from the
group consisting of Hydrogen, Fluoro, Chloro, Bromo, --CHF.sub.2,
--CH.sub.2F, --CF.sub.3, --CN and methyl; [0053] R.sup.6 is
selected from the group consisting of C.sub.1-C.sub.6alkyl and a
3-7 membered saturated ring optionally containing one or more
heteroatoms each independently selected from the group consisting
of O, S and N, such C.sub.1-C.sub.6alkyl or 3-7 membered saturated
ring optionally substituted with one or more substituents selected
from the group consisting of Fluoro, C.sub.1-C.sub.3alkyl
optionally substituted with one or more Fluoro, --CN, OH; [0054]
R.sup.7 represents hydrogen;
[0055] or a pharmaceutically acceptable salt or a solvate
thereof.
[0056] In a second aspect, the invention provides compound of
Formula (II)
##STR00010##
[0057] or Formula (III)
##STR00011##
[0058] or a stereoisomer or tautomeric form thereof, wherein:
[0059] n indicates an integer of 1 or 2; [0060] R.sup.1, R.sup.2and
R.sup.3 are independently selected from the group consisting of
Hydrogen, Fluoro, Chloro, Bromo, --CHF.sub.2, --CH.sub.2F,
--CF.sub.3, --CN and methyl; [0061] R.sup.4 and R.sup.5 are
independently selected from Hydrogen or methyl; [0062] R.sup.6 is
selected from the group consisting of C.sub.1-C.sub.6alkyl and a
3-7 membered saturated ring optionally containing one or more
heteroatoms each independently selected from the group consisting
of O, S and N, such C.sub.1-C.sub.6alkyl or 3-7 membered saturated
ring optionally substituted with one or more substituents selected
from the group consisting of Fluoro, C.sub.1-C.sub.3alkyl
optionally substituted with one or more Fluoro, --CN, OH; [0063]
R.sup.7 represents hydrogen;
[0064] or a pharmaceutically acceptable salt or a solvate
thereof.
[0065] In a first embodiment, compounds of Formula (I), (II) or
(III) are provided wherein R.sup.6 is selected from the group
consisting of C.sub.1-C.sub.6alkyl and a 3-7 membered saturated
ring optionally containing one or more heteroatoms each
independently selected from the group consisting of 0, S and N,
such C.sub.1-C.sub.6alkyl or 3-7 membered saturated ring optionally
substituted with one or more substituents selected from the group
consisting of Fluoro, C.sub.1-C.sub.3alkyl, --CN, OH.
[0066] In one embodiment, compounds of the present invention are
provided wherein le is selected from hydrogen, Fluoro, Chloro,
--CHF.sub.2, --CN, --CF.sub.3 or methyl. In a further embodiment,
least two of R.sup.1, R.sup.2 and R.sup.3 are Fluoro, Chloro or
Bromo. In a further embodiment, R.sup.1 is not Hydrogen.
[0067] In another embodiment, R.sup.4 is methyl.
[0068] In yet another embodiment, compounds according to the
invention are indicated wherein R.sup.6 contains a 3-7 membered
saturated ring optionally containing one oxygen, such 3-7 membered
saturated ring optionally substituted with methyl. Preferably,
R.sup.6 is a 4 or 5 membered saturated ring containing one oxygen,
such 4 or 5 membered saturated ring optionally substituted with
methyl.
[0069] In another embodiment, R.sup.6 is a branched
C.sub.1-C.sub.6alkyl optionally substituted with one or more
Fluoro.
[0070] Preferred compounds according to the invention are provided
wherein the stereochemical configuration of atom (*) is as
follows
##STR00012##
[0071] Another embodiment of the present invention relates to those
compounds of Formula (I), (II) or (III) or any subgroup thereof as
mentioned in any of the other embodiments wherein one or more of
the following restrictions apply:
##STR00013##
[0072] represents
##STR00014##
[0073] and R.sup.6 is selected from the group consisting of
C.sub.1-C.sub.6alkyl optionally being substituted with one or more
Fluoro;
##STR00015##
[0074] represents
##STR00016##
[0075] and R.sup.2 is Hydrogen or Fluoro. [0076] (c) R.sup.1 and
R.sup.3are independently selected from the group consisting of
Hydrogen, Fluoro, Chloro --CN and methyl. [0077] (d) R.sup.2 is
Hydrogen or Fluoro and R.sup.1 and R.sup.3 are independently
selected from the group consisting of Hydrogen, Fluoro, Chloro and
--CN. [0078] (e) R.sup.6 comprises a branched C.sub.3-C.sub.6alkyl
optionally substituted with one or more Fluoro, or wherein R.sup.6
comprises a C.sub.3-C.sub.6cycloalkyl wherein such
C.sub.3-C.sub.6cycloalkyl is substituted with C.sub.1-C.sub.3alkyl
substituted with one or more Fluoro.
[0079] Further combinations of any of the embodiments are also in
the scope of the present invention.
[0080] Preferred compounds according to the invention are compounds
1-35 or a stereoisomer or tautomeric form thereof as referenced to
in Table 1.
[0081] In a further aspect, the present invention concerns a
pharmaceutical composition comprising a therapeutically or
prophylactically effective amount of a compound of formula (I) as
specified herein, and a pharmaceutically acceptable carrier. A
prophylactically effective amount in this context is an amount
sufficient to prevent HBV infection in subjects being at risk of
being infected. A therapeutically effective amount in this context
is an amount sufficient to stabilize HBV infection, to reduce HBV
infection, or to eradicate HBV infection, in infected subjects. In
still a further aspect, this invention relates to a process of
preparing a pharmaceutical composition as specified herein, which
comprises intimately mixing a pharmaceutically acceptable carrier
with a therapeutically or prophylactically effective amount of a
compound of formula (I), as specified herein.
[0082] Therefore, the compounds of the present invention or any
subgroup thereof may be formulated into various pharmaceutical
forms for administration purposes. As appropriate compositions
there may be cited all compositions usually employed for
systemically administering drugs. To prepare the pharmaceutical
compositions of this invention, an effective amount of the
particular compound, optionally in addition salt form, as the
active ingredient is combined in intimate admixture with a
pharmaceutically acceptable carrier, which carrier may take a wide
variety of forms depending on the form of preparation desired for
administration. These pharmaceutical compositions are desirable in
unitary dosage form suitable, particularly, for administration
orally, rectally, percutaneously, or by parenteral injection. For
example, in preparing the compositions in oral dosage form, any of
the usual pharmaceutical media may be employed such as, for
example, water, glycols, oils, alcohols and the like in the case of
oral liquid preparations such as suspensions, syrups, elixirs,
emulsions and solutions; or solid carriers such as starches,
sugars, kaolin, lubricants, binders, disintegrating agents and the
like in the case of powders, pills, capsules, and tablets. Because
of their ease in administration, tablets and capsules represent the
most advantageous oral dosage unit forms, in which case solid
pharmaceutical carriers are employed. For parenteral compositions,
the carrier will usually comprise sterile water, at least in large
part, though other ingredients, for example, to aid solubility, may
be included. Injectable solutions, for example, may be prepared in
which the carrier comprises saline solution, glucose solution or a
mixture of saline and glucose solution. Injectable suspensions may
also be prepared in which case appropriate liquid carriers,
suspending agents and the like may be employed. Also included are
solid form preparations intended to be converted, shortly before
use, to liquid form preparations. In the compositions suitable for
percutaneous administration, the carrier optionally comprises a
penetration enhancing agent and/or a suitable wetting agent,
optionally combined with suitable additives of any nature in minor
proportions, which additives do not introduce a significant
deleterious effect on the skin. The compounds of the present
invention may also be administered via oral inhalation or
insufflation in the form of a solution, a suspension or a dry
powder using any art-known delivery system.
[0083] It is especially advantageous to formulate the
aforementioned pharmaceutical compositions in unit dosage form for
ease of administration and uniformity of dosage. Unit dosage form
as used herein refers to physically discrete units suitable as
unitary dosages, each unit containing a predetermined quantity of
active ingredient calculated to produce the desired therapeutic
effect in association with the required pharmaceutical carrier.
Examples of such unit dosage forms are tablets (including scored or
coated tablets), capsules, pills, suppositories, powder packets,
wafers, injectable solutions or suspensions and the like, and
segregated multiples thereof.
[0084] The compounds of formula (I) are active as inhibitors of the
HBV replication cycle and can be used in the treatment and
prophylaxis of HBV infection or diseases associated with HBV. The
latter include progressive liver fibrosis, inflammation and
necrosis leading to cirrhosis, end-stage liver disease, and
hepatocellular carcinoma.
[0085] Due to their antiviral properties, particularly their
anti-HBV properties, the compounds of formula (I) or any subgroup
thereof, are useful in the inhibition of the HBV replication cycle,
in particular in the treatment of warm-blooded animals, in
particular humans, infected with HBV, and for the prophylaxis of
HBV infections. The present invention furthermore relates to a
method of treating a warm-blooded animal, in particular human,
infected by HBV, or being at risk of infection by HBV, said method
comprising the administration of a therapeutically effective amount
of a compound of formula (I).
[0086] The compounds of formula (I), as specified herein, may
therefore be used as a medicine, in particular as medicine to treat
or prevent HBV infection. Said use as a medicine or method of
treatment comprises the systemic administration to HBV infected
subjects or to subjects susceptible to HBV infection of an amount
effective to combat the conditions associated with HBV infection or
an amount effective to prevent HBV infection.
[0087] The present invention also relates to the use of the present
compounds in the manufacture of a medicament for the treatment or
the prevention of HBV infection.
[0088] In general it is contemplated that an antiviral effective
daily amount would be from about 0.01 to about 50 mg/kg, or about
0.01 to about 30 mg/kg body weight. It may be appropriate to
administer the required dose as two, three, four or more sub-doses
at appropriate intervals throughout the day. Said sub-doses may be
formulated as unit dosage forms, for example, containing about 1 to
about 500 mg, or about 1 to about 300 mg, or about 1 to about 100
mg, or about 2 to about 50 mg of active ingredient per unit dosage
form.
[0089] The present invention also concerns combinations of a
compound of formula (I) or any subgroup thereof, as specified
herein with other anti-HBV agents. The term "combination" may
relate to a product or kit containing (a) a compound of formula
(I), as specified above, and (b) at least one other compound
capable of treating HBV infection (herein designated as anti-HBV
agent), as a combined preparation for simultaneous, separate or
sequential use in treatment of HBV infections. In an embodiment,
the invention concerns combination of a compound of formula (I) or
any subgroup thereof with at least one anti-HBV agent. In a
particular embodiment, the invention concerns combination of a
compound of formula (I) or any subgroup thereof with at least two
anti-HBV agents. In a particular embodiment, the invention concerns
combination of a compound of formula (I) or any subgroup thereof
with at least three anti-HBV agents. In a particular embodiment,
the invention concerns combination of a compound of formula (I) or
any subgroup thereof with at least four anti-HBV agents.
[0090] The term anti-HBV agent also includes compounds capable of
treating HBV infection via immunomodulation. Examples of
immunomodulators are interferon-.alpha. (IFN-.alpha.), pegylated
interferon-.alpha. or stimulants of the innate immune system such
as Toll-like receptor 7 and/or 8 agonists. One embodiment of the
present invention relates to combinations of a compound of Formula
(IA) or any subgroup thereof, as specified herein with an
immunomodulating compound, more specifically a Toll-like receptor 7
and/or 8 agonist.
[0091] The combination of previously known anti-HBV agents, such as
interferon-.alpha. (IFN-.alpha.), pegylated interferon-.alpha.,
3TC, adefovir or a combination thereof, and, a compound of formula
(I) or any subgroup thereof can be used as a medicine in a
combination therapy.
[0092] Generic Synthesis:
[0093] The substituents represented by R.sup.1,2,3, R.sup.7 or
R.sup.6 in this general synthesis section are meant to include any
substituent or reactive species that is suitable for transformation
into any R.sup.1,2,3 or R.sup.6 substituent according to the
present invention without undue burden for the person skilled in
the art.
[0094] A possible synthesis of compounds of general formula (I) is
described in scheme 1. A N-protected (where Pg is protecting group)
aminocarboxylic acid of general formula (IV) can be selectively
reacted with an aniline of general formula (V), for example by
addition of aniline (V) to a mixture of compound (IV), and a
coupling agent (e.g. HATU) in an aprotic solvent (e.g.
dichloromethane, DMF), along with an organic base (e.g.
triethylamine) resulting in compound (VI). The protecting group
(Pg) can subsequently be deprotected according to known methods
(e.g. For the boc group, deprotection involves addition of a strong
acid like HC1. Benzyl protecting groups are removed via catalytic
hydrogenation via known methods by one skilled in the art.) forming
the amine salt which after solvent removal and addition of base
(e.g. diisopropylethylamine) can be further reacted in one pot with
ethyl chlorooxoacetate at reduced temperature in an aprotic solvent
(e.g. dichloromethane) to afford compounds of type (VIII). The
ester group of (VIII) is then hydrolyzed by known methods (e.g.
addition of an aqueous base). In one pot, the newly formed acid is
generated after decreasing the pH and removal of the solvent under
reduced pressure. The acid functional group is converted to an
amide functional group by use of of a coupling agent (e.g. HATU) in
an aprotic solvent (e.g. dichloromethane, DMF), along with an
organic base (e.g. triethylamine), and amines (IX) resulting in
compounds of formula (I). Alternatively, the ester functionality in
compounds (VIII) can be converted to an amide via reaction with an
amine (IX) in a closed vessel, or optionally in the presence of
lithium bis(trimethylsilyl)amide at 0.degree. C. in a solvent like
THF.
##STR00017##
[0095] Scheme 2 describes another possible synthesis of a compound
of general formula I. A compound of general formula X is reacted
with ethyl chlorooxoacetate, resulting in a compound of general
formula XI. After selective hydrolysis, for example in the presence
of a base like NaOH at 0.degree. C. in MeOH, compound XII is
formed. This compound can be coupled with an amine of general
formula IX in the presence of a coupling agent (e.g. HATU) in an
aprotic solvent (e.g. dichloromethane, DMF), along with an organic
base (e.g. triethylamine). Alternatively, compound XI can be
directely converted into a compound of general formula XIII by
reaction with an amine IX (for example in case of IX equals
isopropylamine,in EtOH at 60.degree. C.) resulting in the selective
formation of a compound of formula XIII. Hydrolysis of the ester
functionality of XIII, result in a compound of general formula XIV,
which can be coupled with an amine of general formula V, for
example under influence of a coupling agent (e.g. HATU) in an
aprotic solvent (e.g. dichloromethane, DMF), along with an organic
base (e.g. triethylamine), resulting in the formation of a compound
of general formula I
##STR00018##
##STR00019##
[0096] A reagent of general formula XVI, can be formed starting
from reacting ethyl chlorooxoacetate with an amine of general
formula IX, followed by ester hydrolysis, as shown in scheme 3.
This reagent XVI, can be coupled with an amine, for example
obtained after deprotection of VI, in the presence of coupling
agent (e.g. HATU) in an aprotic solvent (e.g. dichloromethane,
DMF), along with an organic base (e.g. triethylamine), resulting in
a compound of general formula I.
[0097] General Procedure LCMS Methods
[0098] The High Performance Liquid Chromatography (HPLC)
measurement was performed using a LC pump, a diode-array (DAD) or a
UV detector and a column as specified in the respective methods. If
necessary, additional detectors were included (see table of methods
below). Flow from the column was brought to the Mass Spectrometer
(MS) which was configured with an atmospheric pressure ion source.
It is within the knowledge of the skilled person to set the tune
parameters (e.g. scanning range, dwell time . . . ) in order to
obtain ions allowing the identification of the compound's nominal
monoisotopic molecular weight (MW). Data acquisition was performed
with appropriate software.
[0099] Compounds are described by their experimental retention
times (R.sub.t) and ions. If not specified differently in the table
of data, the reported molecular ion corresponds to the [M+H].sup.+
(protonated molecule) and/or [M-H].sup.- (deprotonated molecule).
In case the compound was not directly ionizable the type of adduct
is specified (i.e. [M+NH.sub.4].sup.+, [M+HCOO].sup.-, etc.). All
results were obtained with experimental uncertainties that are
commonly associated with the method used. Hereinafter, "SQD" means
Single Quadrupole Detector, "MSD" Mass Selective Detector, "RT"
room temperature, "BEH" bridged ethylsiloxane/silica hybrid, "DAD"
Diode Array Detector, "HSS" High Strength silica., "Q-Tof"
Quadrupole Time-of-flight mass spectrometers, "CLND",
ChemiLuminescent Nitrogen Detector, "ELSD" Evaporative Light
Scanning Detector,
[0100] LCMS Methods
[0101] (Flow expressed in mL/min; column temperature (T) in
.degree. C.; Run time in minutes). The instrument used was a
Waters: Acquity.RTM. UPLC.RTM. -DAD and SQD.
TABLE-US-00001 Method Flow Run code Column Mobile phase Gradient
Col T time A Waters: BEH C18 A: 0.1% From 95% A to 0% 0.8 3 (1.7
.mu.m, 2.1 .times. HCOOH + 5% A in 2.5 min, to 5% 55 50 mm)
CH.sub.3OH in A in 0.5 min. H.sub.2O B: CH.sub.3CN B Waters: BEH
C18 A: 10 mM From 95% A to 5% 0.8 2 (1.7 .mu.m, 2.1 .times.
CH.sub.3COONH.sub.4 A in 1.3 min, held 55 50 mm) in 95% H.sub.2O +
for 0.7 min. 5% CH.sub.3CN B: CH.sub.3CN C Waters: HSS T3 A: 10 mM
From 100% A to 0.8 3.5 (1.8 .mu.m, 2.1 .times. CH.sub.3COONH.sub.4
5% A in 2.10 min, 55 100 mm) in 95% H.sub.2O + to 0% A in 5%
CH.sub.3CN 0.90 min, to 5% A B: CH.sub.3CN in 0.5 min D Waters: HSS
T3 A: 10 mM From 100% A to 0.7 3.5 (1.8 .mu.m, CH.sub.3COONH.sub.4
5% A in 2.10 min, 55 2.1 * 100 mm) in 95% H.sub.2O + to 0% A in 5%
CH.sub.3CN 0.90 min, B: CH3CN to 5% A in 0.5 min
[0102] Synthesis of Compounds:
Compound 1:
(S)--N--(3-bromo-4,5-difluorophenyl)-1-(2-oxo-2-(((R)-1,1,1-trifluoroprop-
an-2-yl)amino)acetyl)pyrrolidine-3-carboxamide
##STR00020##
[0104] Step 1. Synthesis of
(S)--N--(3-bromo-4,5-difluorophenyl)pyrrolidine-3-carboxamide.
N-Boc-(3S)-1-pyrrolidine-3-carboxylic acid [CAS 140148-70-5] (1 g,
4.65 mmol), 3-bromo-4,5-difluoroaniline (0.96 g, 4.65 mmol) and
HATU (2.12 g, 5.58 mmol) were added to CH.sub.2Cl.sub.2 (10 mL).
N,N-diisopropylethylamine (2.4 mL, 13.9 mmol) was added and the
resultant mixture stirred at room temperature for 4 hours. The
mixture was partitioned with HCl (1M, aq., 20 mL). The organic
layer was separated and the solvent removed under reduced pressure.
The crude was purified via silica gel column chromatography using a
heptane to ethyl acetate gradient to afford an oil. Subsequent Boc
deprotection HCl (6 M in isopropanol, 15h at room temperature)
afforded
(5)--N--(3-bromo-4,5-difluorophenyl)pyrrolidine-3-carboxamide
hydrochloride that was used as such in the next step without
further purification.
[0105] Step 2. Synthesis of (9-ethyl
2-(3-((3-bromo-4,5-difluorophenyl)carbamoyl)
pyrrolidin-1-yl)-2-oxoacetate. A mixture of
(S)--N--(3-bromo-4,5-difluorophenyl) pyrrolidine-3-carboxamide
hydrochloride (1.8 g), and triethylamine (1.47 mL, 10.54 mmol) in
CH.sub.2Cl.sub.2 (20 mL) was cooled to 0.degree. C. To this mixture
was added ethyl chloro oxoacetate (0.65 mL, 5.8 mmol) dropwise, and
the reaction mixture was stirred for one hour at 0.degree. C.,
followed by the addition of ethyl acetate (100 mL). The organic
layer was washed (1M HCl aq., NaHCO.sub.3 aq., and brine), dried
over magnesium sulfate, the solids were removed by filtration and
the solvent of the filtrate was removed under reduced pressure. The
crude intermediate was used as such without further purification in
the next step.
[0106] Step 3.
(S)-2-(3-((3-bromo-4,5-difluorophenyl)carbamoyl)pyrrolidin-1-yl)-2-oxoace-
tic acid was afforded after the corresponding ethyl ester was
hydrolyzed using sodium hydroxide in ethanol for 15 minutes at room
temperature. The reaction mixture was cooled to 0.degree. C. HCl
(1M aq.) was added to bring the mixture to approximately pH 2.
Brine (30 mL) was added and the mixture was partitioned with ethyl
acetate (3.times.50 mL). The organic layers were pooled, washed
with brine (20 mL), dried over sodium sulfate, the solids were
removed by filtration, and the solvent was removed under reduced
pressure to afford the title compound as an oil. No further
purification was done.
[0107] Step 4. Preparation of
(S)--N--(3-bromo-4,5-difluorophenyl)-1-(2-oxo-2-(((R)-1,1,1-trifluoro-pro-
pan-2-yl)amino)acetyl)pyrrolidine-3-carboxamide. A mixture of
(S)-2-(3-((3-bromo-4,5-difluorophenyl)carbomoyl)pyrrolidin-1-yl)-2-oxoace-
tic acid (450 mg), HATU (0.499 g, 1.31 mmol), diisopropylethylamine
(463 mg, 3.58 mmol), (R)-1,1,1-trifluoro-2-propylamine (135 mg,
1.19 mmol), and DMF (8 mL) were allowed to stir at room temperature
for 2 hours. To the reaction mixture was added ethyl acetate (100
mL). The organic layer was washed with 1M HCl (aq.), sodium
bicarbonate (sat., aq.), and brine. The solvents were removed under
reduced pressure and the crude was purified by reverse phase
preperative HPLC (stationary phase: RP Vydac Denali C18-10 .mu.m,
200 g, 5 cm), mobile phase: 0.25% NH.sub.4HCO.sub.3 solution in
water, CH.sub.3CN). The desired fractions were pooled and the
solvent was removed under reduced pressure to afford compound 1 as
a white solid. Method A, Rt=1.63 min, m/z=470.0 )M-H).sup.-, exact
mass: 471.0, .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.30
(d, J=7.0 Hz, 3 H), 1.97-2.31 (m, 2 H), 3.10-3.27 (m, 1 H),
3.39-3.96 (m, 4 H), 4.51-4.75 (m, 1 H), 7.57-7.80 (m, 2 H), 9.26
(br. s., 1 H), 10.41 (br. s., 1 H)
Compound 2:
(S)--N--(3-bromo-4,5-difluorophenyl)-1-(2-((3-methyloxetan-3-yl)amino)-2--
oxoacetyl)pyrrolidine-3-carboxamide.
##STR00021##
[0109] Compound 2 was made according to the method described for
compound 1 with the exception that, in step 4,
3-methyloxetan-3-amine was employed instead of
(R)-1,1,1-trifluoro-2-propylamine. Method A, Rt=1.44 min, m/z=444.0
(M-H).sup.-, exact mass: 445.0. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.46-1.57 (m, 6 H), 1.92-2.32 (m, 4 H), 3.08-3.24 (m, 2
H), 3.43 (dt, J=12.3, 7.5 Hz, 1 H), 3.49-3.61 (m, 2 H), 3.62-3.77
(m, 2 H), 3.78-3.90 (m, 2 H), 3.99 (dd, J=11.8, 7.6 Hz, 1 H),
4.25-4.37 (m, 4 H), 4.58-4.70 (m, 4 H), 7.55-7.86 (m, 4 H), 9.18
(br. s., 2 H), 10.40 (br. s., 2 H), as a mixture of rotamers.
Compound 3:
(S)--N--(3-bromo-4,5-difluorophenyl)-1-(2-(tert-butylamino)-2-oxoacetyl)--
pyrrolidine-3-carboxamide
##STR00022##
[0111] Compound 3 was made according to the method described for
compound 1 with the exception that, in step four,
2-methylpropan-2-amine was employed instead of
(R)-1,1,1-trifluoro-2-propylamine. Method A, Rt=1.63 min, m/z=430.0
(M-H).sup.-, Exact mass: 431.1. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.24-1.36 (m, 9 H), 1.91-2.29 (m, 2 H), 3.06-3.25 (m, 1
H), 3.37-4.01 (m, 4 H), 7.60-7.80 (m, 2 H), 7.96-8.03 (m, 1 H),
10.39 (br. s., 1 H).
Compound 4:
(3S)--N--(4-Fluoro-3-methylphenyl)-1-{[(1-methylethyl)amino]
(oxo)acetyl}-pyrrolidine-3-carboxamide
##STR00023##
[0113] Step 1. Preparation of (S)-tert-butyl
3-((4-fluoro-3-methylphenyl)carbamoyl) pyrrolidine-1-carboxylate.
N-Boc-(3S)-1-pyrrolidine-3-carboxylic acid CAS [140148-70-5] (20 g,
92.9 mmol), 4-fluoro-3-methylaniline (11.63 g, 92.9 mmol), and N,
N-diisopropylethylamine (48 mL, 279 mmol) were added to
CH.sub.2Cl.sub.2 (300 mL) at room temperature. HATU (42.4 g, 111.5
mmol) was added in small portions and the resultant mixture stirred
at room temperature for 15 hours. The mixture was partitioned with
HCl (1 M, aq., 20 mL). The organic layer was separated and the
solvent removed under reduced pressure. The crude was purified via
silica gel column chromatography using a heptane to ethyl acetate
gradient to afford an oil. Subsequent Boc-deprotection HCl (6 M in
isopropanol, 15 hours at room temperature) afforded
(S)--N--(4-fluoro-3-methylphenyl)pyrrolidine-3-carboxamide
hydrochloride that was used as such in the next step without
further purification.
[0114] Step 2. Preparation of (9-ethyl
2-(3-((4-fluoro-3-methylphenyl)carbamoyl)pyrrolidin-l-yl)-2-oxoacetate.
A mixture of
(S)--N--(4-fluoro-3-methylphenyl)pyrrolidine-3-carboxamide
hydrochloride (0.5 g), and triethylamine (587 mg, 5.80 mmol) in
CH.sub.2Cl.sub.2 (10 mL) was cooled to 0.degree. C. To this mixture
was added ethyl chlorooxoacetate (290 mg, 2.13 mmol) dropwise, and
the reaction mixture stirred for one hour and 20 minutes at
0.degree. C., followed by the addition of ethyl acetate. The
organic layer was washed (1 M HCl aq., NaHCO.sub.3 aq., and brine),
dried over magnesium sulfate, the solids were removed by filtration
and the solvent of the filtrate was removed under reduced pressure.
The crude intermediate was used without further purification in the
next step.
[0115] Step 3. Preparation of
(3S)--N--(4-Fluoro-3-methylphenyl)-1-{[(1-methylethyl)amino]
(oxo)acetyl}pyrrolidine-3-carboxamide. (9-ethyl
2-(3-((4-fluoro-3-methylphenyl)carbamoyl)-pyrrolidin-1-yl)-2-oxoacetate
(300 mg) was dissolved in ethanol (8 mL) and to this was added
isopropylamine (211 mg, 3.58 mmol) as a solution in ethanol (2 mL).
After 3 hours isopropylamine (1 mL, 11.64 mmol) was added. The
reaction mixture was stirred at room temperature in a closed vessel
for 3 days. The solvents were removed under reduced pressure and
the crude was purified by preparative HPLC (stationary phase: RP
Vydac Denali C18, 10 .mu.m, 200 g, 5 cm), mobile phase: 0.25%
NH.sub.4HCO.sub.3 solution in water, CH.sub.3CN). The fractions
were pooled and the solvents were removed under reduced pressure to
afford compound 4 as a white solid. Method A, Rt=1.35 min,
m/z=336.4 (M+H).sup.+, exact mass: 335.2. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.02-1.16 (m, 12 H), 1.93-2.20 (m, 4 H),
2.18-2.22 (m, 6 H), 3.04-3.24 (m, 2 H), 3.40 (dt, J=12.1, 7.7 Hz, 1
H), 3.48-3.60 (m, 2 H), 3.60-3.72 (m, 2 H), 3.73-3.85 (m, 2 H),
3.85-4.01 (m, 3 H), 6.97-7.14 (m, 2 H), 7.33-7.43 (m, 2 H),
7.46-7.61 (m, 2 H), 8.44 (s, 1 H), 8.46 (s, 1 H), 10.02 (s, 1 H),
10.05 (s, 1 H), as a mixture of rotamers. Differential scanning
calorimetry (From 30 to 300.degree. C. at 10.degree. C./min), Peak:
137.99.degree. C.
Compound 5:
(9-1-(2-(cyclopentylamino)-2-oxoacetyl)--N--(4-fluoro-3-methylphenyl)-pyr-
rolidine-3-carboxamide.
##STR00024##
[0117] Compound 5 was made according to the method described for
compound 4 with the exception that in step 3, cyclopentylamine (10
eq.) was employed instead of isopropylamine and the duration of the
reaction at room temperature was two days instead of three. Method
A, Rt=1.49 min, m/z=362.1 (M+H).sup.+, exact mass: 361.2. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.37-1.56 (m, 7 H),
1.57-1.72 (m, 4 H), 1.75-1.89 (m, 4 H), 1.96-2.20 (m, 5 H),
2.18-2.23 (m, 6 H), 3.03-3.25 (m, 2 H), 3.34-3.45 (m, 1 H),
3.48-3.59 (m, 2 H), 3.60-3.70 (m, 2 H), 3.71-3.83 (m, 2 H),
3.87-3.97 (m, 1 H), 3.97-4.11 (m, 2 H), 6.99-7.13 (m, 2 H), 7.38
(dd, J=8.1, 3.7 Hz, 2 H), 7.47-7.59 (m, 2 H), 8.52 (s, 1 H), 8.54
(s, 1 H), 10.03 (s, 1 H), 10.05 (s, 1 H), as a mixture of rotamers.
Differential scanning calorimetry (From 30 to 300.degree. C. at
10.degree. C./min), Peak: 163.50 .degree. C.
Compound 6:
(S)--N--(4-fluoro-3-methylphenyl)-1-(2-(((R)-1-hydroxypropan-2-yl)amino)--
2-oxoacetyl)pyrrolidine-3-carboxamide
##STR00025##
[0119] Compound 6 was made according to the method described for
compound 4, with the exception that in step 3, (R)-2-aminopropanol
(10 eq.) was employed instead of isopropylamine and the duration of
the reaction at room temperature was two days instead of three.
Method A, Rt=1.14 min, m/z=352.0 (M+H).sup.+, exact mass: 351.2.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.06 (d, J=6.6 Hz,
6 H), 1.93-2.15 (m, 3 H), 2.18-2.22 (m, 6 H), 3.07-3.18 (m, 3 H),
3.26-3.30 (m, 1 H), 3.32-3.46 (m, 4 H), 3.49-3.61 (m, 2 H),
3.61-3.75 (m, 2 H), 3.76-3.90 (m, 4 H), 3.99 (dd, J=11.7, 7.7 Hz,
1H),4.67-4.80 (m, 2 H), 7.00-7.11 (m, 2 H), 7.31-7.45 (m, 2 H),
7.46-7.58 (m, 2 H), 8.29 (s, 1 H), 8.31 (s, 1 H), 10.03 (s, 1 H),
10.05 (s, 1 H), as a mixture of rotamers.
Compound 7:
(3S)--N--(4-Fluoro-3-methylphenyl)-1-{[(3-methyloxetan-3-yl)amino]-(oxo)a-
cetyl}pyrrolidine-3-carboxamide
##STR00026##
[0121] Compound 7 was made according to the method described for
compound 4 with the exception that in step 3,
3-methyloxetan-3-amine (2 eq.) was employed instead of
isopropylamine. The reaction proceeded at 50.degree. C. for 1 week
instead of at room temperature for three days as described for
compound 4. Method B, Rt=0.73 min, m/z=364.4 (M+H).sup.+, exact
mass: 363.2. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.49-1.56 (m, 6 H), 1.93-2.22 (m, 5 H), 2.19-2.21 (m, 6 H),
3.07-3.25 (m, 2 H), 3.37-3.47 (m, 2 H), 3.50-3.60 (m, 2 H),
3.62-3.75 (m, 2 H), 3.76-3.89 (m, 2 H), 3.98 (dd, J=11.6, 7.6 Hz, 1
H), 4.27-4.35 (m, 4 H), 4.60-4.70 (m, 4 H), 7.01-7.11 (m, 1 H),
7.35-7.45 (m, 1 H), 7.49-7.57 (m, 2 H), 9.20 (br. s., 1 H), 9.25
(s, 1 H), 10.10 (br. s., 1 H), 10.12 (s, 1 H), as a mixture of
rotamers.
Compound 8:
(3S)--N--(4-Fluoro-3-methylphenyl)-1-[{[(1R)-1-methylpropyl]amino}(oxo)ac-
etyl]pyrrolidine-3-carboxamide
##STR00027##
[0123] Compound 8 was made according to the method described for
compound 4, with the exception that in step 3, (R)-butan-2-amine (2
eq.) was employed instead of isopropylamine. The duration of the
reaction at room temperature was 18 hours instead of three days as
described for compound 4. Method B, Rt=0.87 min, m/z=348.2
(M-H).sup.-, exact mass: 349.2. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 0.77-0.87 (m, 6 H), 1.05-1.10 (m, 6 H), 1.37-1.55 (m, 4
H), 1.93-2.27 (m, 4 H), 2.19-2.22 (m, 6 H), 3.07-3.26 (m, 2 H),
3.37-3.46 (m, 1 H), 3.49-3.60 (m, 2 H), 3.62-3.86 (m, 6 H), 3.96
(dd, J=11.7, 7.7 Hz, 1 H), 7.02-7.11 (m, 2 H), 7.35-7.44 (m, 2 H),
7.49-7.56 (m, 2 H), 8.38 (s, 1 H), 8.40 (s, 1 H), 10.03 (s, 1 H),
10.06 (s, 1 H), as a mixture of rotamers.
Compound 9:
(3S)--N--(4-Fluoro-3-methylphenyl)-1-{oxo[(3S)-tetrahydrofuran-3-ylamino]-
-acetyl}pyrrolidine-3-carboxamide
##STR00028##
[0125] Compound 9 was made according to the method described for
compound 4, with the exception that in step 3,
(S)-tetrahydrofuran-3-amine (2 eq.) was employed instead of
isopropylamine. The reaction proceeded at 50.degree. C. for 2.5
days instead of at room temperature for three days as described for
compound 4. Method B, Rt=0.72 min, m/z=364.1 (M+H).sup.+, exact
mass: 363.2. .sup.114 NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.80-1.91 (m, 2 H), 1.96-2.26 (m, 6 H), 2.19-2.21 (m, 6 H),
3.07-3.23 (m, 2 H), 3.36-3.45 (m, 1 H), 3.47-3.59 (m, 4 H),
3.61-3.73 (m, 4 H), 3.74-3.85 (m, 6 H), 3.93 (dd, J=11.4, 7.7 Hz, 1
H), 4.20-4.35 (m, 2 H), 7.01-7.12 (m, 2 H), 7.33-7.45 (m, 2 H),
7.47-7.57 (m, 2 H), 8.80 (s, 1 H), 8.82 (s, 1 H), 10.03 (s, 1 H),
10.05 (s, 1 H), as a mixture of rotamers.
Compound 10: (2S,
3S)-N-(4-Fluoro-3-methylphenyl)-2-methyl-1-{[(3-methyloxetan-3-yl)-amino]-
(oxo)acetylIpyrrolidine-3-carboxamide
##STR00029##
[0127] Step 1. Preparation of (9-methyl
2-methyl-1-(1-phenylethyl)-4,5-dihydro-1H-pyrrole-3-carboxylate.
The title compound was prepared according to methods provided in
Tetrahedron Letters, Vol. 33, No. 30, pp. 4311-4312, 1992 and
references cited therein.
[0128] Step 2. Preparation of (2S,3S)-methyl
2-methyl-1-((S)-1-phenylethyl)pyrrolidine-3-carboxylate. To a
solution of (S)-methyl
2-methyl-1-(1-phenylethyl)-4,5-dihydro-1H-pyrrole-3-carboxylate
(5.92 g, 24.1 mmol) in acetonitrile (190 mL) was added acetic acid
(2.07 mL, 36.2 mmol). The reaction mixture was cooled to 0.degree.
C. then sodium triacetoxyborohydride (7.67 g, 36.17 mmol) was added
and stirring was continued at 0.degree. C. for 3 hours. The solvent
was removed under reduced pressure, the crude was reconstituted in
CH.sub.2Cl.sub.2 and Na.sub.7CO.sub.3 (sat., aq.) was added. The
mixture was stirred vigorously. The organic layer was removed,
washed with water, then dried over magnesium sulfate. The solids
were removed by filtration and the solvent of the filtrate was
removed under reduced pressure. The obtained crude oil was purified
by silica gel column chromatography using a heptane/ ethyl acetate
gradient (100/0 to 70/30). The best fractions were pooled and the
solvents were removed under reduced pressure. The oil was
triturated in heptane to afford a white solid, (2S, 3S)-methyl
2-methyl-1-((5)-1-phenylethyl)pyrrolidine-3-carboxylate. Method C,
Rt=1.75 min, m/z=248.4 (M+H).sup.+, exact mass: 247.2. .sup.1H NMR
(chloroform-d) fits the data described in Tetrahedron Letters, Vol.
33, No. 30, pp. 4311-4312, 1992.
[0129] Step 3. Preparation of Lithium
(2S,3S)-2-methyl-14(S)-1-phenylethyl)pyrrolidine-3-carboxylate
(2S,3S)-methyl
2-methyl-14(S)-1-phenylethyl)pyrrolidine-3-carboxylate (100 mg,
0.40 mmol) was dissolved in THF (1.2 mL). To this was added lithium
hydroxide (14 mg, 0.61 mmol) in distilled water (200 .mu.L) and
methanol (50 .mu.L) and the mixture became clear. The resulting
mixture was stirred for 18 hours. The solvent was removed under
reduced pressure and the residue was used without further
purification in the next step.
[0130] Step 4. Preparation of
(2S,3S)--N--(4-fluoro-3-methylphenyl)-2-methyl-1-((S)-1-phenylethyl)-pyrr-
olidine-3-carboxamide. 4-fluoro-3-methylaniline (253 mg, 2.02 mmol)
was added to a mixture of lithium
(2S,3S)-2-methyl-14(S)-1-phenylethyl)pyrrolidine-3-carboxylate (472
mg), HATU (1.15 g, 3.03 mmol), and N,N-diisopropylethylamine (0.7
mL, 4.04 mmol) in CH.sub.2Cl.sub.2. The mixture stirred at room
temperature for 1 hour. The solution was diluted in
CH.sub.2Cl.sub.2 and water, the organic layer was removed, dried
over MgSO.sub.4 and solids were removed by filtration. The solvent
was removed under reduced pressure and the crude was purified by
silica gel chromatography using a heptane/ethyl acetate (100/0 to
70/30) gradient. The best fractions were pooled and the solvent
removed under reduced pressure to afford a white solid,
(2S,3S)--N--(4-fluoro-3-methylphenyl)-2-methyl-1-((S)-1-phenylethyl)pyrro-
lidine-3-carboxamide. Method C, Rt=1.87 min, m/z=341.2 (M+H).sup.+,
exact mass: 340.2. .sup.1H NMR (360 MHz, CHLOROFORM-d) .delta. ppm
1.26 (d, J=6.6 Hz, 3 H), 1.36 (d, J=7.0 Hz, 3 H), 1.82-1.97 (m, 1
H), 2.02-2.18 (m, 1 H), 2.26 (d, J=1.8 Hz, 3 H), 2.56-2.73 (m, 2
H), 2.76-2.88 (m, 1 H), 2.88-2.99 (m, 1 H), 4.08 -4.25 (m, 1 H),
6.85-6.98 (m, 1 H), 7.22-7.45 (m, 7 H), 9.52 (br. s., 1 H)
[0131] Step 5. Preparation of
(2S,3S)--N--(4-fluoro-3-methylphenyl)-2-methylpyrrolidine-3-carboxamide.
To a solution containing
(2S,3S)--N--(4-fluoro-3-methylphenyl)-2-methyl-1-((S)-1-phenylethyl)pyrro-
lidine-3-carboxamide (395 mg, 1.16 mmol) in methanol (20 mL) was
added 10% Pd/C (123 mg) under a nitrogen atmosphere. The reaction
mixture was placed under hydrogen atmosphere and stirred for 24
hours. Hydrogen was removed, the reaction mixture was filtered
through decalite, and the residue was concentrated under reduced
pressure to afford a colorless oil which was used without further
purification in the next step.
[0132] Step 6. Preparation of ethyl
2-((2S,3S)-3-((4-fluoro-3-methylphenyl)carbamoyl)-2-methylpyrrolidin-1-yl-
)-2-oxoacetate. Ethyl oxalyl chloride (0.23 mL, 2.06 mmol) was
added dropwise to a solution of
(2S,3S)--N--(4-fluoro-3-methylphenyl)-2-methylpyrrolidine-3-carboxamide
(244 mg, 1.03 mmol) and diisopropylethylamine (0.71 mL, 4.12 mmol)
in anhydrous CH.sub.2Cl.sub.2 (10 mL) under nitrogen atmosphere at
room temperature. The reaction mixture stirred at room temperature
overnight. HCl (0.5 M, aq.) was added to the reaction mixture. The
organic layer was removed, washed with NaHCO.sub.3 (aq., sat.) and
brine, dried over Na.sub.2SO.sub.4, the solids were removed by
filtration and the solvent of the filtrate were removed under
reduced. The residue was purified by silica gel column
chromatography using a heptane/ethyl acetate (100/0 to 30/70)
gradient to afford the title compound as an oil that was dried
under vacuum at 50.degree. C. for 2 hours and used without further
purification.
[0133] Step 7. Preparation of
2-((2S,3S)-3-((4-fluoro-3-methylphenyl)carbamoyl)-2-methylpyrrolidin-1-yl-
)-2-oxoacetic acid. To a solution of
2-((2S,3S)-3-((4-fluoro-3-methylphenyl)carbamoyl)-2-methylpyrrolidin-1-yl-
)-2-oxoacetate (204 mg, 0.61 mmol) in ethanol (5 mL) was added
dropwise NaOH (1M aq., 1.82 mL). The reaction stirred at room
temperature for 2 hours, then was diluted in CH.sub.2Cl.sub.2 and
water. The layers were separated and the aqueous layer was
acidified with HCl (1M aq.), the acid precipitated and was
reconstituted in CH.sub.2Cl.sub.2. The aqueous layer was extracted
with CH.sub.2Cl.sub.2. The combined organic layers were dried over
Na.sub.2SO.sub.4, the solids were removed by filtration, and the
solvent of the filtrate was removed under reduced pressure to
afford the title compound. Method C, Rt=1.02 min, m/z=307.0
(M-H).sup.-, exact mass: 308.1.
[0134] Step 8. Preparation of
(2S,3S)--N--(4-Fluoro-3-methylphenyl)-2-methyl-1-{[(3-methyloxetan-3-yl)a-
mino](oxo)acetyl}pyrrolidine-3-carboxamide. To a solution of
2-((2S,3S)-3-((4-fluoro-3-methylphenyl)carbamoyl)2-methylpyrrolidin-l-yl)-
-2-oxoacetic acid (128 mg, 0.42 mmol), HATU (236.79 mg, 1.5 eq) and
DIPEA (145 .mu.L, 2 eq) in CH.sub.2Cl.sub.2 (5 mL) was added
3-methyloxetan-3-amine (36 mg, 0.42 mmol) and the reaction mixture
was stirred overnight at room temperature. To the reaction mixture
was added CH.sub.2Cl.sub.2 and HCl (1M, aq.). The layers were
separated and the organic layer was washed with NaHCO.sub.3 (sat.,
aq.) and brine. The combined organic layers were dried over
Na.sub.2SO.sub.4, the solids were removed by filtration and the
filtrate was concentrated under reduced pressure. The crude was
purified by preparative HPLC (stationary phase: RP X-Bridge Prep
C18 OBD-10 .mu.m, 30.times.150 mm), mobile phase: 0.25%
NH.sub.4HCO.sub.3 solution in water, CH.sub.3CN). The best
fractions were pooled and the solvent was removed under reduced
pressure to afford the title compound 10.
[0135] Method C, Rt=1.46 min, m/z=376.0 (M-H).sup.-, exact mass:
377.2. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 0.99-1.05
(m, 6 H), 1.53 (m, J=4.2 Hz, 6 H), 1.86-2.05 (m, 2 H), 2.18-2.23
(m, 6 H), 2.25-2.36 (m, 2 H), 3.02-3.23 (m, 2 H), 3.38-3.70 (m, 3
H), 3.83-3.95 (m, 1 H), 4.27-4.35 (m, 4 H), 4.46-4.57 (m, 1 H),
4.60-4.66 (m, 4 H), 4.81-4.94 (m, 1 H), 6.99-7.12 (m, 2 H),
7.33-7.42 (m, 2 H), 7.45-7.55 (m, 2 H), 9.17 (s, 1 H), 9.26 (s, 1
H), 9.94 (s, 1 H), 10.00 (s, 1 H), as a 1/1 mixture of
rotamers.
Compound 11:
(S)--N--(3-chloro-4,5-difluorophenyl)-1-(2-oxo-2-(((R)-1,1,1-trifluoropro-
pan-2-yl)amino)acetyl)pyrrolidine-3-carboxamide
##STR00030##
[0137] Compound 11 was made according to the method described for
compound 1, step one, with the exception that
3-chloro-4,5-difluoroaniline was employed instead of
3-bromo-4,5-difluoroaniline. The coupling reaction to afford the
title compound was done according to the procedure described for
compound 13, step two, with the exception that (R)
-1,1,1-trifluoro-2-propylamine was employed instead of
1-(trifluoromethyl)-cyclopropanamine. Method B, Rt=1.02 min,
m/z=426.1 (M-H).sup.-, exact mass: 427.1. .sup.11-1NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.30 (d, J=7.0 Hz, 3 H) 1.98-2.28 (m, 2
H) 3.07-3.27 (m, 1 H) 3.41-4.04 (m, 4 H) 4.54-4.75 (m, 1 H)
7.46-7.72 (m, 2 H) 9.17-9.33 (m, 1 H) 10.43 (m, 1 H), as a mixture
of rotamers.
Compound 12:
(3S)--N--(4-Fluoro-3-methylphenyl)-1-{[(1-methylethyl)amino]
(oxo)-acetyl}piperidine-3-carboxamide
##STR00031##
[0139] Step 1. Preparation of (S)-tert-butyl
3-((4-fluoro-3-methylphenyl) carbamoyl)piperidine-1-carboxylate. A
mixture of (S)-1-boc-piperidine-3-carboxylic acid CAS [88495-54-9 ]
(9 g, 39.3 mmol), 4-fluoro-3-methylaniline (4.91 g, 39.3 mmol), and
CH.sub.2Cl.sub.2 (90 mL) was cooled to 0.degree. C. followed by the
addition of diisopropylethylamine (20.5 mL, 117.8 mmol) and HATU
(17.9 g, 47.1 mmol). The reaction mixture stirred at 0.degree. C.
for 2 hours followed by the addition of citric acid (sat., aq., 100
mL), NaHCO.sub.3 (sat., aq., 100 mL), and brine. The organic layer
was dried over Na.sub.2SO.sub.4, the solids were removed by
filtration and the solvents were removed under reduced pressure.
The crude was purified using a petroleum ether/ethyl acetate
gradient (from 100/1 to 3/1). The best fractions were pooled and
the solvent was removed under reduced pressure. .sup.1H NMR (400
MHz, CHLOROFORM-d) .delta. ppm 1.26-1.37 (m, 1 H), 1.39 (s, 9 H),
1.59 (qd, J=12.1, 3.4 Hz, 1 H), 1.69 (d, J=13.2 Hz, 1 H), 1.91 (d,
J=12.6 Hz, 1 H), 2.19 (d, J=1.8 Hz, 3 H), 2.40 (tt, J=11.0, 3.7 Hz,
1 H), 2.75 (t, J=11.7 Hz, 1 H), 2.97 (br. s., 1 H), 3.86 (d, J=13.1
Hz, 1 H), 4.03 (br. s., 1 H), 7.05 (t, J=9.3 Hz, 1 H), 7.31-7.42
(m, 1 H), 7.51 (dd, J=7.0, 2.3 Hz, 1 H), 9.97 (s, 1 H)
[0140] Subsequent deprotection of the boc group was possible via
addition of CH.sub.2Cl.sub.2 (100 mL) and HCl (100 mL, in dioxane)
at room temperature for 24 hours to afford the
(S)--N--(4-fluoro-3-methylphenyl)piperidine-3-carboxamide
hydrochloride intermediate.
[0141] .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.49-1.87
(m, 3 H), 1.95-2.08 (m, 1 H), 2.19 (d, J=2.0 Hz, 3 H), 2.80-2.93
(m, 2 H), 3.00 (q, J=10.4 Hz, 1 H), 3.17 (d, J=12.0 Hz, 1 H), 3.29
(d, J=11.0 Hz, 1 H), 7.07 (t, J=9.2 Hz, 1 H), 7.35-7.45 (m, 1 H),
7.52 (dd, J=7.0, 2.3 Hz, 1 H), 8.90 (d, J=11.2 Hz, 1 H), 9.12 (m,
J=9.5 Hz, 1 H), 10.31 (s, 1 H)
[0142] Step 2. The preparation of compound 12 followed analogous
procedures as in the synthesis step 2 of compound 4 with the
exception that
(S)--N--(4-fluoro-3-methylphenyl)piperidine-3-carboxamide
hydrochloride was employed in the reaction with ethyl
chlorooxoacetate instead of
(S)--N--(4-fluoro-3-methylphenyl)pyrrolidine-3-carboxamide
hydrochloride. Then, as in the subsequent step three in the method
described for compound 4, isopropylamine was used in a closed
vessel to afford compound 12. Method C, Rt=1.47 min, m/z=350.2
(M+H).sup.+, exact mass: 349.2. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.03-1.12 (m, 12 H) 1.30-1.52 (m, 2 H) 1.60-1.71 (m, 2
H) 1.71-1.81 (m, 2 H) 1.92-2.09 (m, 2 H) 2.17-2.21 (m, 6 H)
2.38-2.46 (m, 1 H) 2.53-2.58 (m, 1 H) 2.69-2.81 (m, 2 H) 3.03 (t,
J=11.5 Hz, 1 H) 3.26 (dd, J=13.3, 10.5 Hz, 1 H) 3.68 (d, J=13.3 Hz,
1 H) 3.77 (d, J=13.3 Hz, 1 H) 3.83-3.96 (m, 2 H) 4.18 (d, J=12.9
Hz, 1 H) 4.36 (d, J=12.9 Hz, 1 H) 7.02-7.09 (m, 2 H) 7.33-7.44 (m,
2 H) 7.50 (d, J=6.9 Hz, 2 H) 8.47-8.58 (m, 2 H) 9.96 (s, 2 H), a
mixture of rotamers.
Compound 13:
(S)--N--(3-chloro-4,5-difluorophenyl)-1-(2-oxo-2-41-(trifluoromethyl)
cyclopropyl)amino)acetyl)pyrrolidine-3-carboxamide
##STR00032##
[0144] Step 1. Preparation of (S)-t-butyl
3-((3-chloro-4,5-difluorophenyl)carbamoyl)
pyrrolidine-l-carboxylate. The title compound was prepared
according to the procedure in step 1 of compound 1 with the
exception that 3-chloro-4,5-difluoroaniline was employed instead of
3-bromo-4,5-difluoroaniline. Boc group deprotection and reaction
with ethyl chlorooxoacetate then proceed according to the methods
described.
[0145] Step 2. Preparation of
(S)--N--(3-chloro-4,5-difluorophenyl)-1-(2-oxo-2-((1-(trifluoromethyl)
cyclopropyl)amino)acetyl)pyrrolidine-3-carboxamide. A solution of
(S)-2-(343-chloro-4,5-difluorophneyl)carbamoyl)pyrrolidin-1-yl)-2-oxoacet-
ic acid (0.33 g, 0.99 mmol) in DMF (10 mL) was cooled to 5.degree.
C. Then diisopropylethylamine (0.513 mL, 2.98 mmol) and
1-(trifluoromethyl)-cyclopropanamine (0.092 mL, 0.992 mmol) were
added and stirred at 5.degree. C. A solution of HATU (0.414 g,
1.091 mmol) in DMF (2 mL) was added dropwise at 5.degree. C. The
solution was stirred at 5.degree. C. for 1 h. The reaction quenched
with water and neutralised with HCl (1M, aq.), brine (15 mL) was
added and the compound was extracted with ethyl acetate. The
organic layer was removed, dried with MgSO.sub.4, the solids were
removed by filtration and the solvents removed under reduced
pressure to afford a solid. The solid was dissolved in CH.sub.3CN
with heat and cooled to ambient temperature. The precipitate was
removed by filtration and the filtate was concentrated under
reduced pressure. The crude was purified by silica flash column
chromatography using a heptane/ethyl acetate gradient (30/70 to
0/100). The desired fractions were collected and evaporated to
dryness to afford compound 13 as a white solid. Method B, Rt=1.02
min, m/z=438.1 (M-H).sup.-, exact mass: 439.1. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.04-1.13 (m, 2 H) 1.22-1.31 (m, 2H)
1.97-2.27 (m, 2 H) 3.09-3.24 (m, 1 H) 3.36-4.00 (m, 4 H) 7.49-7.72
(m, 2 H) 9.44 (s, 1 H) 10.43 (br. s., 1 H), as a mixture of
rotamers.
Compound 14:
(S)--N--(4-fluoro-3-(trifluoromethyl)phenyl)-1-(2-oxo-2-4(R)-1,1,1-triflu-
oropropan-2-yl)amino)acetyl)pyrrolidine-3-carboxamide
##STR00033##
[0147] Compound 14 was made according to the method described for
compound 1, with the exception that, in step 1,
4-fluoro-3-(trifluoromethyl)aniline was employed instead of
3-bromo-4,5-difluoroaniline. The coupling reaction to afford the
title compound was done according to the procedure described for
compound 13, step two, with the exception that
(R)-1,1,1-trifluoro-2-propylamine was employed instead of
1-(trifluoromethyl)-cyclopropanamine. Method B, Rt=1.01 min,
m/z=442.1 (M-H), exact mass: 443.1. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.30 (d, J=7.0 Hz, 3 H), 1.87-2.37 (m, 2
H), 3.13-3.27 (m, 1 H), 3.37-3.98 (m, 4 H), 4.34-4.77 (m, 1 H),
7.41-7.55 (m, 1 H), 7.76-7.90 (m, 1 H), 8.01-8.25 (m, 1 H), 9.27
(br. s., 1 H), 10.50 (br. s., 1 H)
Compound 15:
(S)--N--(3-chloro-4-fluorophenyl)-1-(2-oxo-2-(((R)-1,1,1-trifluoropropan--
2-yl)amino)acetyl)pyrrolidine-3-carboxamide
##STR00034##
[0149] Compound 15 was made according to the methods described for
the synthesis of compound 1, with the exception that, in step one,
3-chloro-4-fluoroaniline was used instead of
3-bromo-4,5-difluoroaniline. The coupling reaction to afford the
title compound was done according to the procedure described for
compound 13, step two, with the exception that
(R)-1,1,1-trifluoro-2-propylamine was employed instead of
1-(trifluoromethyl)-cyclopropanamine. Method B, Rt=0.96 min,
m/z=408.1 (M-H).sup.-, exact mass: 409.1. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.30 (d, J=7.0 Hz, 3 H), 1.91-2.30 (m, 2
H), 3.10-3.27 (m, 1 H), 3.38-4.02 (m, 4 H), 4.52-4.71 (m, 1 H),
7.32-7.41 (m, 1 H), 7.43-7.51 (m, 1 H), 7.86-7.99 (m, 1 H), 9.26
(br. s., 1 H), 10.34 (br. s., 1 H), a mixture of rotamers.
Compound 16:
(S)--N--(3-chloro-4,5-difluorophenyl)-1-(2-oxo-2-((1,1,1-trifluoro-2-meth-
yl-propan-2-yl)amino)acetyl)pyrrolidine-3-carboxamide
##STR00035##
[0151] Compound 16 was prepared according to the method to prepare
compound 13 with the exception that
1,1,1-trifluoro-2-methylpropan-2-amine was employed in step two,
instead of 1-(trifluoromethyl)-cyclopropanamine. Method B, Rt=1.08
min, m/z=440.1 (M-H).sup.-, exact mass: 441.1. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.54 (s, 6 H) 1.98-2.31 (m, 2 H)
3.06-3.28 (m, 1 H) 3.40-3.97 (m, 4 H) 7.50-7.80 (m, 2 H) 8.56 (m, 1
H) 10.44 (br. s., 1 H), as a mixture of rotamers.
Synthesis of compound 17:
N-(4-fluoro-3-methylphenyl)-5-methyl-1-(2-((3-methyloxetan-3-yl)amino)-2--
oxoacetyl)pyrrolidine-3-carboxamide
##STR00036##
[0153] Step 1. Preparation of
1-(t-butoxycarbonyl)-5-methylpyrrolidine-3-carboxylic acid. The
title compound was prepared as a mixture of diastereomers according
to methods found in WO2010059658 (p 211), starting from methyl
2-chloro-5-methyl-1H-pyrrole-3-carboxylate which is described in
Foley, L., Tetrahedron Letters 1994, vol. 35, p. 5989.
[0154] Step 2. Preparation of t-butyl
4-((4-fluoro-3-methylphenyl)carbamoyl)-2-methylpyrrolidine-1-carboxylate.
4-fluoro-3-methylaniline (1.09 g, 8.72 mmol) was added to a
solution of 1-(t-butoxycarbonyl)-5-methylpyrrolidine-3-carboxylic
acid (2 g, 8.72 mmol), DIPEA (4.33 mL, 26.17 mmol), and HATU (4.98
g, 14.09 mmol) in CH.sub.2Cl.sub.2 (50 mL). The reaction mixture
stirred for 1 h at room temperature, then partitioned with water.
The organic layer was removed, dried over MgSO.sub.4, the solids
were removed by filtration, and the solvent of the filtrate was
removed under reduced pressure. The crude was purified via silica
gel column chromatography resulting in the title compound. Method
C, Rt=1.96 min, m/z=335.0 (M-H).sup.-, and 1.98 min, m/z=335.1
(M-H).sup.- exact mass: 336.2.
[0155] Step 3. Preparation of ethyl
2-(4-((4-fluoro-3-methylphenyl)carbamoyl)-2-methylpyrrolidin-1-yl)2-oxoac-
etate. To a solution of t-butyl
44(4-fluoro-3-methylphenyl)carbamoyl)-2-methylpyrrolidine-1-carboxylate
in CH.sub.2Cl.sub.2 under an atmosphere of nitrogen was added TFA
dropwise. The reaction mixture stirred at room temperature for 2
hours. The solvent was removed under reduced pressure and the crude
was reconstituted in CH.sub.2Cl.sub.2 and NaOH (1 M, aq.). The
mixture was stirred vigorously for 5 minutes. The layers were
separated and the aqueous layer was extracted with
CH.sub.2Cl.sub.2. The combined organic layers were dried over
MgSO.sub.4, the solids were removed by filtration and the filtrate
was concentrated under reduced pressure to afford an oil. To this
oil was added anhydrous CH.sub.2Cl.sub.2 (50 mL), and triethylamine
(1.09 g, 7.83 mmol). To the resulting solution was added ethyl
oxalyl chloride (0.44 mL, 3.92 mmol) dropwise at room temperature,
then stirred for 18 hours. HCl (0.5 M aq.) was added to the
reaction mixture. The organic layer was removed, dried over
MgSO.sub.4, the solids were removed by filtration and the filtrate
was concentrated to afford an oil, dried under vacuum at 50.degree.
C. for 4 hours and used without further purification.
[0156] Step 4. Preparation of
2-(4-((4-fluoro-3-methylphenyl)carbamoyl)-2-methylpyrrolidin-l-yl)-2-oxoa-
cetic acid. The ester hydrolysis of ethyl
2-(4-((4-fluoro-3-methylphenyl)carbamoyl)-2-methylpyrrolidin-1-yl)-2-oxoa-
cetate was achieved according to the method described in step 7 of
compound 10.
[0157] Step 5. Preparation of
N-(4-fluoro-3-methylphenyl)-5-methyl-1-(2-((3-methyloxetan-3-yl)amino)-2--
oxoacetyl)pyrrolidine-3-carboxamide. The title compound was
prepared according to the procedure in step 8 in the synthesis of
compound 10. Isomers were isolated via preparative SFC (stationary
phase: Whelk-O (R, R) 20.times.250 mm), mobile phase: CO.sub.2,
EtOH/iPrOH (50/50) with 0.2% iPrNH.sub.2). The desired fractions
were collected, and the solvent was removed under reduced pressure
to afford compounds 17a (119 mg), 17b (116 mg), 17c (78 mg), and
17d (94 mg) named in order of elution.
TABLE-US-00002 LC-MS Method, m/z Compound Rt (min) (M + H).sup.+
Configuration 17a C, 1.39 378.2 (3R,5S) or (3S,5R) 17b C, 1.39
378.2 (3R,5S) or (3S,5R) 17c C, 1.37 378.2 (3S,5S) or (3R,5R) 17d
C, 1.37 378.2 (3S,5S) or (3R,5R)
[0158] Compound 17a: .sup.1H NMR (600 MHz, DMSO-d.sub.6) .delta.
ppm 1.21 (d, J=6.3 Hz, 3 H), 1.26 (d, J=6.2 Hz, 3 H), 1.53 (s, 3
H), 1.54 (s, 3 H), 1.75 (ddd, J=12.7, 10.1, 8.1 Hz, 1 H), 1.87
(ddd, J=13.0, 7.5, 5.6 Hz, 1 H), 2.19-2.22 (m, 6 H), 2.41 (dt,
J=12.6, 7.5 Hz, 1 H), 2.46-2.53 (m, 1 H), 3.01-3.12 (m, 2 H), 3.52
(dd, J=12.2, 7.9 Hz, 1 H), 3.65 (dd, J=11.4, 9.8 Hz, 1 H), 3.90
(dd, J=12.2, 8.1 Hz, 1 H), 4.01-4.07 (m, 1 H), 4.09 (dd, J=11.4,
7.5 Hz, 1 H), 4.29-4.35 (m, 4 H), 4.37-4.48 (m, 1 H), 4.62-4.67 (m,
4 H), 7.05-7.09 (m, 2 H), 7.37-7.42 (m, 2 H), 7.49-7.53 (m, 2 H),
9.19 (s, 1 H), 9.23 (s, 1 H), 10.02 (s, 1 H), 10.04 (s, 1 H), as a
mixture of rotamers.
[0159] Compound 17b: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.21 (d, J=6.2 Hz, 3 H), 1.26 (d, J=6.2 Hz, 3 H), 1.49-1.56 (m,
6 H), 1.75 (ddd, J=12.7, 10.0, 8.0 Hz, 1 H), 1.87 (ddd, J=13.0,
7.4, 5.8 Hz, 1 H), 2.17-2.23 (m, 6 H), 2.41 (dt, J=12.7, 7.5 Hz, 1
H), 2.45-2.54 (m, 1 H), 2.96-3.13 (m, 2 H), 3.52 (dd, J=12.1, 7.9
Hz, 1 H), 3.65 (dd, J=11.4, 9.8 Hz, 1 H), 3.91 (dd, J=12.2, 8.0 Hz,
1 H), 3.98-4.15 (m, 2 H), 4.27-4.36 (m, 4 H), 4.37-4.49 (m, 1 H),
4.59-4.70 (m, 4 H), 7.07 (t, J=9.1 Hz, 2 H), 7.34-7.44 (m, 2 H),
7.46-7.55 (m, 2 H), 9.18 (s, 1 H), 9.22 (s, 1 H), 10.01 (s, 1 H),
10.03 (br. s., 1 H), as a mixture of rotamers.
[0160] Compound 17c: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 1.13-1.27 (m, 6 H), 1.51 (s, 3 H), 1.53 (s, 3 H), 1.86 (ddd,
J=12.3, 6.8, 2.9 Hz, 1 H), 1.98 (dd, J=12.0, 6.9 Hz, 1 H),
2.07-2.17 (m, 2 H), 2.18-2.23 (m, 6 H), 3.26-3.31 (m, 2 H),
3.58-3.70 (m, 2 H), 3.84 (dd, J=11.7, 7.9 Hz, 1 H), 3.92-4.01 (m, 1
H), 4.17-4.26 (m, 1 H), 4.27-4.36 (m, 4 H), 4.54-4.62 (m, 1 H),
4.61-4.66 (m, 4 H), 7.01-7.12 (m, 2 H), 7.32-7.43 (m, 2 H),
7.47-7.57 (m, 2 H), 9.17 (s, 1 H), 9.20 (s, 1 H), 10.03 (s, 1 H),
10.07 (s, 1 H), as a mixture of rotamers.
[0161] Compound 17d: .sup.1H NMR (600 MHz, DMSO-d.sub.6) .delta.
ppm 1.20 (d, J=6.5 Hz, 3 H), 1.21 (d, J=6.5 Hz, 3 H), 1.51 (s, 3
H), 1.53 (s, 3 H), 1.86 (ddd, J=12.3, 6.8, 2.9 Hz, 1 H), 1.98 (dd,
J=12.1, 6.8 Hz, 1 H), 2.10-2.18 (m, 2 H), 2.18-2.23 (m, 6 H),
3.28-3.32 (m, 2 H), 3.60-3.68 (m, 2 H), 3.84 (dd, J=11.6, 7.9 Hz, 1
H), 3.97 (dd, J=11.7, 7.8 Hz, 1 H), 4.18-4.26 (m, 1 H), 4.28-4.35
(m, 4 H), 4.56-4.61 (m, 1 H), 4.62-4.67 (m, 4 H), 7.03-7.11 (m, 2
H), 7.35-7.42 (m, 2 H), 7.48-7.55 (m, 2 H), 9.19 (s, 1 H), 9.22 (s,
1 H), 10.04 (s, 1 H), 10.09 (s, 1 H), as a mixture of rotamers.
Compound 18 :
N-(3-chloro-4,5-difluoro-phenyl)-2,2-dimethyl-142-oxo-2-[[(1R)-2,2,2-trif-
luoro-1-methyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide
##STR00037##
[0163] A mixture of diethyl fumarate (19.05 mL/113.848 mmol) and
2-nitropropane (10.2 mL/113.8 mmol) was treated with KF/basic
alumina (20 g). The reaction mixture was stirred overnight and the
mixture was filtered. The filtrate was concentrated yielding crude
diethyl 2-(1-methyl-1-nitro-ethyl)butanedioate (20 g) which was
used as such.
[0164] .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.10-1.22
(m, 6 H) 1.54 (s, 3 H) 1.58 (s, 3 H) 2.55-2.76 (m, 2 H) 3.52 (dd,
J=11.00, 3.96 Hz, 1 H) 3.99-4.13 (m, 4 H). To a solution of crude
diethyl 2-(1-methyl-l-nitro-ethyl)butanedioate (2200 mg, 8.42
mmol), triethyl amine (1.17 mL/8.42 mmol) and ethanol (100 mL) was
added Pd/C (10%) (448.04 mg/0.421 mmol) under a nitrogen flow. The
resulting mixture was stirred under hydrogen atmosphere at ambient
temperature until 3 equivalents of hydrogen were absorbed. The
catalyst was removed by filtration over dicalite and the filtrate
was evaporated to yield of ethyl
2,2-dimethyl-5-oxo-pyrrolidine-3-carboxylate (1.05 g) as a solid
which was used as such. A mixture of ethyl
2,2-dimethyl-5-oxo-pyrrolidine-3-carboxylate (750 mg / 4.05 mmol)
and lawesson's reagent (983 mg/2.43 mmol) in toluene on molecular
sieves (15 mL) was warmed to 70.degree. C. for 1 hour, cooled and
concentrated in vacuo, resultin in a solid residue. The crude was
purified using silica gel column chromatography (gradient elution:
EtOAc-heptane 0:100 to 100:0) yielding ethyl
2,2-dimethyl-5-thioxo-pyrrolidine-3-carboxylate (432 mg) as a
slightly yellow powder, which was used as such. Method B, Rt=0.66
min, m/z=202.1 (M+H).sup.+, exact mass: 201.1. Ethyl
2,2-dimethyl-5-thioxo-pyrrolidine-3-carboxylate (100 mg, 0.5 mmol)
was dissolved in tetrahydrofuran (2 mL). To this was added ethanol
(2 mL) and the mixture was stirred overnight. The mixture was
filtered over a path of dicalite, rinsed with ethanol and
concentrated in vacuo yielding crude ethyl
2,2-dimethylpyrrolidine-3-carboxylate (50 mg) as a beige powder
which was used as such.
[0165] Ethyl oxalyl chloride (65.35 .mu.L/0.58 mmol) was added drop
wise to a solution of crude ethyl
2,2-dimethylpyrrolidine-3-carboxylate (50 mg, 0.29 mmol) and DIPEA
(0.25 mL/1.46 mmol) in CH.sub.2Cl.sub.2 (2 mL) at room temperature.
The reaction mixture was stirred at room temperature for 1 hour.
Saturated aqueous NaHCO.sub.3 (5mL) and CH.sub.2Cl.sub.2 (5mL) was
added to the reaction mixture and the layers were separated. The
organic layer was dried on MgSO.sub.4, filtered, and evaporated to
dryness. The obtained residue was purified by silica gel column
chromatography using gradient elution from heptane to EtOAc. (100:0
to 0:100). The desired fractions were concentrated in vacuo
yielding ethyl
1-(2-ethoxy-2-oxo-acetyl)-2,2-dimethyl-pyrrolidine-3-carboxylate
(80 mg) as a clear colorless oil which was used as such. Ethyl
1-(2-ethoxy-2-oxo-acetyl)-2,2-dimethyl-pyrrolidine-3-carboxylate
(80 mg, 0.29 mmol) was dissolved in ethanol (1 mL/17.13 mmol) and
cooled on an ice bath. NaOH (0.59 mL/1 M/0.59 mmol) was added, and
the mixture was stirred while cooling was continued for 10 minutes.
HCl (0.59 mL, 1 M, 0.59 mmol) was added drop wise under cooling.
The mixture was concentrated in vacuo. The residue was partioned
between water and Me-THF. The organic layer was separated, dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo, resulting
in 2-(3-ethoxycarbonyl-2,2-dimethyl-pyrrolidin-1-yl)-2-oxo-acetic
acid (70 mg) as an oil which was used as such. A solution of
2-(3-ethoxycarbonyl-2,2-dimethyl-pyrrolidin-1-yl)-2-oxo-acetic acid
(70 mg, 0.29 mmol) in DMF (10 mL) was cooled to 5.degree. C. in an
ice-water bath. Then DIPEA (0.15 mL, 0.75 g/mL, 0.86 mmol) and
(R)-1,1,1-trifluoro-2-propylamine (39.05 mg, 0.35 mmol) were added
and stirred. A solution of HATU (120.36 mg, 0.32 mmol) in DMF (5
mL) was added drop wise while cooling was continued. The obtained
solution was stirred for 1 hour under cooling. The reaction was
quenched with water and neutralised with a 1N HCl solution. Brine
(10 mL) was added and the compound was extracted with EtOAc
(3.times.20 mL). The combined organics were dried with
Na.sub.2SO.sub.4, filtered and evaporated to dryness. This was
purified by flash column chromatography over silica Heptane to
EtOAc (100/0-0/100). The desired fractions were collected and
evaporated to dryness to afford ethyl
2,2-dimethyl-1-[2-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]acety-
l]pyrrolidine-3-carboxylate (70 mg) as a white solid which was used
as such. Ethyl
2,2-dimethyl-142-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetyl-
]pyrrolidine-3-carboxylate (70 mg, 0.21 mmol) was dissolved in THF
(5 mL). To this was added LiOH (17.7 mg, 0.74 mmol) in water (5
mL). MeOH (0.2 mL) was added to dissolve all the reactants. The
mixture was stirred overnight at room temperature. Then it was
concentrated in vacuo untill only water remained. Next, HCl (0.74
mL, 1 M, 0.74 mmol) was added and this was extracted using Me-THF
(3.times.10 mL). The combined extracts were washed with of brine
(20 mL), dried on Na.sub.2SO.sub.4, filtered and concentrated in
vacuo yielding
2,2-dimethyl-1-[2-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]acety-
l]pyrrolidine-3-carboxylic acid (45 mg)
[0166] as a white powder which was used as such.
2,2-dimethyl-142-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetyl-
]pyrrolidine-3-carboxylic acid (45 mg, 0.15 mmol),
3-chloro-4,5-difluoro-aniline (58.02 mg, 0.29 mmol), HATU (110.3
mg, 0.29 mmol) and DIPEA (0.12 mL, 0.75 g/mL, 0.73 mmol) were
dissolved in DMF (0.34 mL, 4.34 mmol). This mixture was stirred at
room temperature for 2 hours. Extra DIPEA (0.12 mL, 0.75 g/mL, 0.73
mmol) was added and the mixture was shaken at 60.degree. C. for 2
hours. This mixture was purified by silica gel column
chromatography using gradient elution from heptane to EtOAc. (100:0
to 0:100) and further via preperative HPLC (Stationary phase:
Uptisphere C18 ODB -10 .mu.m, 200g, 5cm, Mobile phase: 0.25%
NH.sub.4HCO.sub.3 solution in water, MeOH) The desired fractions
were concentrated in vacuo, co-evaporated twice using MeOH and
dried in a vacuum oven at 55.degree. C. for 24 hours yielding
N-(3-chloro-4,5-difluoro-phenyl)-2,2-dimethyl-1-[2-oxo-2-[[(1R)-2,2,2-tri-
fluoro-1-methyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide (6.3
mg) as a white solid. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
ppm 1.35-1.39 (m, 3 H), 1.46-1.49 (m, 3 H), 1.69-1.80 (m, 3 H),
2.01-2.20 (m, 1 H), 2.23-2.43 (m, 1 H), 2.58-2.74 (m, 1 H),
3.86-4.09 (m, 1 H), 4.20-4.47 (m, 1 H), 4.48-4.67 (m, 1 H), 7.08
(s, 1 H), 7.28-7.36 (m, 1 H), 7.41-7.49 (m, 1 H), 7.49-7.65 (m, 1
H). LC method B ; Rt: 1.11 min. m/z: 454.2 (M-H)- Exact mass:
455.1
Compound 19 : (3
S)-1-[2-(tert-butylamino)-2-oxo-acetyl]-N-(3-chloro-2,4-difluoro-phenyl)p-
yrrolidine-3-carboxamide
##STR00038##
[0168] Ethyl
2-[(3S)-3-[(3-chloro-2,4-difluoro-phenyl)carbamoyl]pyrrolidin-1-yl]-2-oxo-
-acetate was obtained similar as described for (S)-ethyl
2-(3-((3-bromo-4,5-difluorophenyl)carbamoyl)
pyrrolidin-1-yl)-2-oxoacetate using 3-chloro-2,4-difluoro-aniline
instead of 3-bromo-4,5-difluoroaniline in step one. Ethyl
2-[(3S)-3-[(3-chloro-2,4-difluoro-phenyl)carbamoyl]pyrrolidin-1-yl]-2-oxo-
-acetate (0.6 g, 1.66 mmol) was dissolved in tetrahydrofuran (15
mL). To this was added tert-butylamine (0.18 g, 2.49 mmol) and this
mixture was cooled in an ice-water bath. Then lithium
bis(trimethylsilyl)amide (1M in toluene) (4.99 mL, 1 M, 4.99 mmol)
was added drop wise over a period of 5 minutes. The resulting
mixture was stirred for 1 hour while cooling was continued. Then it
was quenched using NH.sub.4Cl (saturated/50 mL). This was extracted
using EtOAc (3.times.50 mL). The combined extracts were washed with
brine (50 mL), dried on Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure. The obtained residue was purified by silica
gel column chromatography using gradient elution from heptane to
EtOAc. (100:0 to 0:100) and further via Prep HPLC (Stationary
phase: RP XBridge Prep C18 OBD-10 .mu.m, 30.times.150 mm, Mobile
phase: 0.25% NH.sub.4HCO.sub.3 solution in water, MeOH) yielding
compound 19 (136 mg) as a white powder. Method B, Rt=0.95 min,
m/z=386.2 (M-H).sup.-, Exact mass: 387.1. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.31 (s, 9 H), 1.85-2.30 (m, 2 H),
3.15-4.33 (m, 5 H), 7.26-7.34 (m, 1 H), 7.65-7.86 (m, 1 H), 8.00
(m, 1 H), 10.08 (br. s., 1 H) as a mixture of rotamers.
Compound 20 : (3
S)-142-(tert-butylamino)-2-oxo-acetyl]-N-(3-cyano-4-fluorophenyl)-pyrroli-
dine-3-carboxamide
##STR00039##
[0170] Compound 20 was prepared similarly as described for compound
19, using 5-amino-2-fluoro-benzonitrile instead of
3-chloro-2,4-difluoro-aniline in step one. Method D, Rt=1.66 min,
m/z=359.1 (M-H).sup.-, Exact mass: 360.2. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.30 (m, 9 H), 1.92-2.29 (m, 2 H),
3.06-3.27 (m, 1 H), 3.34-4.01 (m, 4 H), 7.38-7.58 (m, 1 H),
7.77-7.89 (m, 1 H), 7.91-8.07 (m, 1 H), 8.09-8.19 (m, 1 H),
10.32-10.59 (m, 1 H) as a mixture of rotamers.
Compound 21 :
(3S)--N--(3-chloro-2,4-difluoro-phenyl)-142-oxo-2-[[(1R)-2,2,2-trifluoro--
1-methyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide
##STR00040##
[0172] Compound 21 was prepared similarly as described for compound
19, using (R)-1,1,1-trifluoro-2-propylamine instead of
tert-butylamine. Method B, Rt=0.97 min, m/z=426.2 (M-H).sup.-,
Exact mass: 427.1. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.27-1.33 (m, 3 H), 1.95-2.28 (m, 2 H), 3.33-4.00 (m, 5 H),
4.52-4.72 (m, 1 H), 6.97-7.48 (m, 1 H), 7.60-7.91 (m, 1 H),
9.01-9.47 (m, 1 H), 9.90-10.28 (m, 1 H) as a mixture of
rotamers.
Compound 22 :
(3S)--N--(3-cyano-4-fluoro-phenyl)-142-oxo-2-[[(1R)-2,2,2-trifluoro-1-met-
hyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide
##STR00041##
[0174] Compound 22 was prepared similarly as described for compound
20, using (R)-1,1,1-trifluoro-2-propylamine propylamine instead of
tert-butylamine. Method B, Rt=0.87 min, m/z=399.2 (M-H).sup.-,
Exact mass: 400.1. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.30 (d, J=7.0 Hz, 3 H), 1.96-2.30 (m, 2 H), 3.11-3.28 (m, 1 H),
3.38-4.00 (m, 4 H), 4.41-4.77 (m, 1 H), 7.42-7.56 (m, 1 H),
7.78-7.90 (m, 1 H), 8.04-8.23 (m, 1 H), 9.26 (br. s., 1 H), 10.50
(br. s., 1 H) as a mixture of rotamers.
Compound 23 : (3 S)-N44-fluoro-3-(trifluoromethyl)phenyl]-142-(i
sopropylamino)-2-oxo-acetyl]pyrrolidine-3-carboxamide
##STR00042##
[0176] Compound 23 was prepared similarly as described for compound
14, using isopropylamine instead of
(R)-1,1,1-trifluoro-2-propylamine. Method B, Rt=0.94 min, m/z=388.2
(M-H).sup.-, Exact mass: 389.1. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.00-1.17 (m, 6 H), 1.94-2.30 (m, 2 H), 3.10-3.26 (m, 1
H), 3.35-4.02 (m, 5 H), 7.36-7.58 (m, 1 H), 7.75-7.95 (m, 1 H),
8.04-8.19 (m, 1 H), 8.36-8.53 (m, 1 H), 10.37-10.63 (m, 1 H) as a
mixture of rotamers.
Compound 24 : (3
S)-N44-fluoro-3-(trifluoromethyl)phenyl]-142-[[(1R)-1-methylpropyl]-amino-
]-2-oxo-acetyl]pyrrolidine-3-carboxamide
##STR00043##
[0178] Compound 24 was prepared similarly as described for compound
14, using (R)-(-)-2-aminobutane instead of
(R)-1,1,1-trifluoro-2-propylamine. Method B, Rt=0.99 min, m/z=402.2
(M-H).sup.-, Exact mass: 403.2. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 0.76-0.88 (m, 3 H), 1.00-1.15 (m, 3 H), 1.35-1.53 (m, 2
H), 1.94-2.29 (m, 2 H), 3.11-3.26 (m, 1 H), 3.37-4.01 (m, 5 H),
7.40-7.53 (m, 1 H), 7.79-7.89 (m, 1 H), 8.05-8.16 (m, 1 H),
8.29-8.46 (m, 1 H), 10.35-10.60 (m, 1 H) as a mixture of
rotamers.
Compound 25 : (3
S)--N--(3-chloro-4-fluoro-phenyl)-142-oxo-24[1-(trifluoromethyl)cyclo-[pr-
opyl]amino]acetyl]pyrrolidine-3-carboxamide
##STR00044##
[0180] Compound 25 was prepared similarly as described for compound
15, using 1-(trifluoro-methyl)cyclopropan-1-amine instead of
(R)-1,1,1-trifluoro-2-propylamine. Method B, Rt=0.97 min, m/z=420.1
(M-H).sup.-, Exact mass: 421.1..sup.1-H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 0.95-1.14 (m, 2 H), 1.22-1.29 (m, 2 H), 1.95-2.29 (m, 2
H), 3.09-3.24 (m, 1 H), 3.34-3.98 (m, 4 H), 7.32-7.41 (m, 1 H),
7.42-7.53 (m, 1 H), 7.88-7.97 (m, 1 H), 9.44 (s, 1 H), 10.19-10.35
(m, 1 H) as a mixture of rotamers.
Compound 26 : (3
S)--N--(3-chloro-4-fluoro-phenyl)-1-[2-oxo-2-[[(1S)-2,2,2-trifluoro-1-met-
hyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide
##STR00045##
[0182] Compound 26 was prepared similarly as described for compound
15, using (S)-1,1,1-trifluoro-2-propylamine instead of
(R)-1,1,1-trifluoro-2-propylamine. Method B, Rt=0.97 min, m/z=408.1
(M-H).sup.-, Exact mass: 409.1 .sup.1-14 NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.26-1.37 (m, 3 H), 1.95-2.29 (m, 2 H),
3.10-3.27 (m, 1 H), 3.34-3.98 (m, 4 H), 4.52-4.71 (m, 1 H),
7.32-7.41 (m, 1 H), 7.43-7.52 (m, 1 H), 7.86-7.99 (m, 1 H),
9.17-9.33 (m, 1 H), 10.22-10.35 (m, 1 H) as a mixture of
rotamers
Compound 27 :
(2S)--N--(3-cyano-4-fluoro-phenyl)-142-(isopropylamino)-2-oxo-acetyl]-2-m-
ethyl-pyrrolidine-3-carboxamide
##STR00046##
[0184] (2S,3S)-methyl
2-methyl-1-((S)-1-phenylethyl)pyrrolidine-3-carboxylate (1.9 g,
7.68 mmol) was dissolved in methanol (50 mL). This was added to
Pd/C (10%/0.82 g, 0.77 mmol) under nitrogen. The mixture was
stirred under a hydrogen atmosphere at room temperature for 24
hours. The resulting mixture was filtered over a dicalite plug and
rinsed using of methanol (100 mL). The filtrate was concentrated in
vacuo yielding methyl (2S,3S)-2-methylpyrrolidine-3-carboxylate
(830 mg) as a clear oil. Ethyl 2-chloro-2-oxo-acetate (1.3 mL,
11.59 mmol) was added drop wise to a solution of methyl
(2S,3S)-2-methylpyrrolidine-3-carboxylate (0.83 g, 5.8 mmol) and
diisopropylethylamine (4.99 mL, 28.98 mmol) in dry dichloromethane
(5 mL) at room temperature. The reaction mixture was stirred at
room temperature for 1 h. Saturated aqueous NaHCO.sub.3 (5 mL) were
added to the reaction mixture and the layers were separated. Then
it was extracted using dichloromethane (2.times.10 mL). The
combined extracts were dried on Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The obtained crude was purified by silica
gel column chromatography using gradient elution from heptane to
EtOAc. (100:0 to 0:100). The desired fractions were concentrated in
vacuo yielding methyl
(2S,3S)-1-(2-ethoxy-2-oxo-acetyl)-2-methyl-pyrrolidine-3-carboxylate
(890 mg) of as a yellow oil.
[0185] methyl
(25,35)-1-(2-ethoxy-2-oxo-acetyl)-2-methyl-pyrrolidine-3-carboxylate
(250 mg, 1 mmol) was dissolved in ethanol (10 mL) and
isopropylamine (1698 .mu.L, 19.94 mmol) and the mixture was stirred
at 60.degree. C. for 2 hours. The mixture was concentrated in
vacuo. The obtained oil was purified by silica gel column
chromatography using gradient elution from heptane to EtOAc. (100:0
to 0:100). The desired fractions were concentrated under reduced
pressure yielding methyl
(2S)-1-[2-(isopropylamino)-2-oxo-acetyl]-2-methyl-pyrrolidine-3-carboxyla-
te (380 mg) as a clear oil which was used as such.
[0186] Methyl
(2S)-142-(isopropylamino)-2-oxo-acetyl]-2-methyl-pyrrolidine-3-carboxylat-
e (0.38 g, 1.48 mmol) was dissolved in tetrahydrofuran (10 mL) and
this was stirred at room temperature. To this was added LiOH
(178mg, 7.41 mmol) in water (2 mL) followed by methanol (2 mL). The
resulting mixture was stirred at room temperature for 2 hours.
Then, HCl (1M in H.sub.2O) (7.41 mL, 1 M, 7.41 mmol) was added and
the mixture was concentrated in vacuo until only water remained.
Water (5 mL) was added and this solution was extracted using
2-methyl-tetrahydrofuran (3.times.15 mL). The combined extracts
were washed with brine (15 mL), dried on Na.sub.2SO.sub.4, filtered
and concentrated in vacuo yielding
(2S)-142-(isopropylamino)-2-oxo-acetyl]-2-methyl-pyrrolidine-3-carboxylic
acid (312 mg) which was used as such.
[0187]
(2S)-1-[2-(isopropylamino)-2-oxo-acetyl]-2-methyl-pyrrolidine-3-car-
boxylic acid (104 mg, 0.43 mmol) was dissolved in
N,N-dimethylformamide (1 mL). Then HATU (0.18 g, 0.47 mmol) was
added and this mixture was stirred for 20 minutes. Then DIPEA (0.22
mL, 0.75 g/mL, 1.29 mmol) was added folowed by
5-amino-2-fluorobenzonitrile (0.12 g, 0.86 mmol). The reaction
mixture was stirred at 50.degree. C. for 4 hours. Then this mixture
was cooled to room temperature and injected directly onto a silica
plug. The mixture was purified by silica gel column chromatography
using gradient elution from heptane to EtOAc. (100:0 to 0:100) and
further by preperative HPLC (Stationary phase: RP SunFire Prep C18
OBD-10 .mu.m, 30.times.150mm, Mobile phase: 0.25% NH.sub.4HCO.sub.3
solution in water, MeOH) The desired fractions were concentrated
under reduced pressure and co-evaporated twice with methanol
(2.times.15mL) and dried in a vacuum oven at 55.degree. C. for 18
hours yielding compound 27 (57 mg) as a white powder. Method B,
Rt=0.81 (31%) and 0.83 min (69%), m/z=359.2 (M-H).sup.-, Exact
mass: 360.2
Compound 28 :
(2S)--N--(3-chloro-2,4-difluoro-phenyl)-142-(isopropylamino)-2-oxo-acetyl-
]-2-methyl-pyrrolidine-3-carboxamide
##STR00047##
[0189] Compound 28 was prepared from
(2S)-142-(isopropylamino)-2-oxo-acetyl]-2-methyl-pyrrolidine-3-carboxylic
acid similarly as described for compound 27, using
3-chloro-2,4-difluoro-aniline instead of
5-amino-2-fluorobenzonitrile.Method B, Rt=0.91 (48%) and 0.92 min
(52%), m/z=386 (M-H).sup.-, Exact mass: 387.1.
Compound 29 :
(2S)--N--(3-chloro-4,5-difluoro-phenyl)-142-(isopropylamino)-2-oxo-acetyl-
]-2-methyl-pyrrolidine-3-carboxamide
##STR00048##
[0191] Compound 29 was prepared from
(2S)-1-[2-(isopropylamino)-2-oxo-acetyl]-2-methyl-pyrrolidine-3-carboxyli-
c acid similarly as described for compound 27, using
3-chloro-4,5-difluoro-aniline instead of
5-amino-2-fluorobenzonitrile. The diastereomeric mixture 29 (63 mg)
was separated via Preperative SFC (Stationary phase: Chiralpak
Diacel AD 20.times.250 mm, Mobile phase: CO.sub.2, MeOH with 0.2%
iPrNH.sub.2), resulting in 29a (second eluting, 20 mg) and 29b
(first eluding, 13.2 mg after further purification by silica gel
column chromatography using gradient elution from heptane to iPrOH.
(100:0 to 65:35)). 29: Method B, 0.98 (42%) and 1.02 min (58%),
m/z=386 (M-H).sup.-, Exact mass: 387.1.29a: Method D, Rt=1.89,
m/z=386.1 (M-H).sup.-, Exact mass: 387.1; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 0.95-1.05 (m, 3 H), 1.06-1.16 (m, 6 H),
1.82-2.11 (m, 1 H), 2.14-2.44 (m, 1 H), 3.04-3.26 (m, 1 H),
3.35-4.10 (m, 3 H), 4.32-4.97 (m, 1 H), 7.33-7.85 (m, 2 H),
8.20-8.73 (m, 1 H), 10.07-10.68 (m, 1 H) as a mixture of rotamers.
29b: Method B, Rt=0.97 m/z=386.2 (M-H)", Exact mass: 387.1. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.03-1.14 (m, 6 H),
1.23-1.31 (m, 3 H), 1.93-2.11 (m, 1 H), 2.14-2.30 (m, 1 H),
2.72-2.93 (m, 1 H), 3.30-4.70 (m, 4 H), 7.56-7.73 (m, 2 H),
8.28-8.54 (m, 1 H), 10.22-10.60 (m, 1 H) as a mixture of
rotamers.
Compound 30 : (3
S)-N43-(difluoromethyl)-4-fluoro-phenyl]-142-oxo-2-[[(1
S)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide
##STR00049##
[0193] Ethyl
2-[(3S)-3-[[3-(difluoromethyl)-4-fluoro-phenyl]carbamoyl]pyrrolidin-1-yl]-
-2-oxo-acetate was prepared similarly as described for (9-ethyl
2-(3-((3-bromo-4,5-difluorophenyl)carbamoyl)
pyrrolidin-l-yl)-2-oxoacetate using
3-(difluoromethyl)-4-fluoro-aniline instead of
3-bromo-4,5-difluoroaniline. Compound 30 was prepared from ethyl
2-[(3S)-34[3-(difluoromethyl)-4-fluoro-phenyl]carbamoyl]pyrrolidin--
1-yl]-2-oxo-acetate similar as described for the synthesis of
compound 19 from ethyl
2-[(3S)-3-[(3-chloro-2,4-difluoro-phenyl)carbamoyl]pyrrolidin-1-yl]-2-oxo-
-acetate using (S)-1,1,1-trifluoro-2-propylamine instead of
tert-butylamine. Method B, Rt=0.92 min., m/z=424.1 (M-H).sup.-,
Exact mass: 425.1. .sup.11-1NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.19-1.40 (m, 3 H), 1.92-2.30 (m, 2 H), 3.08-3.27 (m, 1 H),
3.37-4.03 (m, 4 H), 4.47-4.78 (m, 1 H), 7.20 (m, J=54.4 Hz, 1 H),
7.29-7.41 (m, 1 H), 7.55-7.80 (m, 1 H), 7.86-8.04 (m, 1 H), 9.25
(br. s., 1 H), 10.30-10.40 (m, 1 H) as a mixture of rotamers.
Compound 31: (3
S)-N43-(difluoromethyl)-4-fluoro-phenyl]-142-(isopropylamino)-2-oxo-acety-
l]pyrrolidine-3-carboxamide
##STR00050##
[0195] Compound 31 was prepared similarly as described for compound
30, using isopropylamine instead of
(S)-1,1,1-trifluoro-2-propylamine. Method B, Rt=0.83 min.,
m/z=370.2 (M-H).sup.-, Exact mass: 371.1. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 0.75-1.42 (m, 6 H), 1.95-2.29 (m, 2 H),
3.05-3.26 (m, 1 H), 3.36-4.04 (m, 5 H), 7.20 (m, J=54.1,1 H),
7.28-7.37 (m, 1 H), 7.63-7.78 (m, 1 H), 7.87-8.03 (m, 1 H),
8.40-8.50 (m, 1 H), 10.25-10.41 (m, 1 H) as a mixture of
rotamers.
Compound 32 : (3
S)-142-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl] amino]
acetyl]-N-(3,4,5-trifluorophenyl)pyrrolidine-3-carboxamide
##STR00051##
[0197] Boc-(3S)-1-pyrrolidine-3-carboxylic acid (1.5 g, 6.97 mmol)
and 3,4,5-trifluoroaniline (2.51 g, 17.05 mmol) and HATU (3.18 g,
8.36 mmol) were dissolved in DMF (5 mL). To this was added
N,N-diisopropylethylamine (3.6 mL, 0.75 g/mL, 20.91 mmol). The
resulting mixture was stirred at room temperature for 2 h. The
reaction mixture was loaded on a column and was purified by silica
gel column chromatography using gradient elution from heptane to
EtOAc. (100:0 to 0:100). The desired fractions were concentrated in
vacuo yielding tert-butyl
(3S)-3-[(3,4,5-trifluorophenyl)carbamoyl]pyrrolidine-1-carboxylate
(2.32 g). Method B, Rt=1.13 min., m/z=343.1 (M-H).sup.-, Exact
mass: 344.1. HCl (6M in iPrOH, 10 mL, 6 M, 60 mmol) was added to
tert-butyl
(3S)-3-[(3,4,5-trifluorophenyl)carbamoyl]pyrrolidine-1-carboxylate
(2.3 g, 6.35 mmol) in CH.sub.2Cl.sub.2 (50 mL) and this was stirred
at room temperature for 5 days at room temperature. The reaction
was concentrated. The residue was taken up in CH.sub.2Cl.sub.2 (40
mL) and a white precipitate was formed which was collected on a
glass filter and dried in a vacuum oven at 55.degree. C. yielding
(3S)--N--(3,4,5-trifluorophenyl)pyrrolidine-3-carboxamide
hydrochloride (1600 mg) as a bright white powder which was used as
such. Method B, Rt=0.69 min., m/z=243.0 (M-H).sup.-, Exact mass:
244.1.
[0198] Ethyl 2-chloro-2-oxo-acetate (1.98 mL, 1.22 g/mL, 17.69
mmol) was added to a solution of (R)-1,1,1-trifluoro-2-propylamine
(2 g, 17.69 mmol) and triethylamine (4.9 mL, 35.37 mmol) in
CH.sub.2Cl.sub.2 (20 mL). The reaction mixture was stirred for 1
hour. NaOH (1M in H.sub.2O) (26.5 mL, 1 M, 26.53 mmol) was added
and the reaction mixture was stirred vigourously for 2 hours. The
organic layer was removed and the aqueous layer was acidified with
HCl. The compound was extracted with diethylether (4 X 25 mL). The
combined organic layers were dried over Na.sub.2SO.sub.4, filtered
and evaporated to dryness resulting in
2-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetic acid
(2.72 g) as a white powder.
[0199] (3S)--N--(3,4,5-trifluorophenyl)pyrrolidine-3-carboxamide
hydrochloride (200 mg) and
2-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetic acid
(118 mg, 0.64 mmol) were dissolved in DMF (2 mL). HATU (266.74 mg,
0.7 mmol) and DIPEA (0.44 mL, 0.75 g/mL, 2.55 mmol) were added
succesively. The reaction mixture was stirred at room temperature.
The reaction mixture was loaded on a column and purified using
silica gel column chromatography (ethyl acetate in heptane from 0
to 100%) to afford compound 32 (83 mg) as a white powder. Method B,
Rt=1.04 min., m/z=410.1 (M-H)", Exact mass: 411.1. Differential
scanning calorimetry: melting point at 197.3.degree. C. (From 30 to
300.degree. C. at 10.degree. C./min). .sup.1E1 NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.30 (d, J=7.0 Hz, 3 H), 1.92-2.30 (m, 2
H), 3.09-3.26 (m, 1 H), 3.38-3.99 (m, 4 H), 4.50-4.70 (m, 1 H),
7.40-7.60 (m, 2 H), 9.20-9.31 (m, 1 H), 10.42-10.49 (m, 1 H) as a
mixture of rotamers.
Compound 33:
(2S)--N--(3-chloro-4,5-difluoro-phenyl)-2-methyl-142-oxo-2-[(1R)-(2,2,2-t-
rifluoro-1-methyl-ethyl)amino]acetyl]pyrrolidine-3-carboxamide
##STR00052##
[0201] Methyl
(2S,3S)-1-(2-ethoxy-2-oxo-acetyl)-2-methyl-pyrrolidine-3-carboxylate
(2200 mg, 9.04 mmol) in of methanol (50 mL) was cooled in an
ice-water bath. To this was added NaOH (1M in H.sub.2O) (9.95 mL, 1
M, 9.95 mmol) drop wise and the mixture was stirred for 30 minutes.
The reaction was quenched with HCl (1 M in H.sub.2O) (9.5 mL, 1 M,
9.5 mmol) and concentrated to keep 20 mL residue. The residue was
extracted with 2-methyl THF (2.times.20 mL). The combined organic
layers were dried (Na.sub.2SO.sub.4) and evaporated to dryness to
afford
2-[(2S,3S)-3-methoxycarbonyl-2-methyl-pyrrolidin-1-yl]-2-oxo-acetic
acid (1930 mg) as light yellow solid.
[0202] A solution of
2-[(2S,3S)-3-methoxycarbonyl-2-methyl-pyrrolidin-1-yl]-2-oxo-acetic
acid (800 mg, 3.64 mmol) in DMF (4 mL, 51.44 mmol) and
(R)-1,1,1-trifluoro-2-propylamine (494 mg, 4.37 mmol) was cooled to
0.degree. C. in an ice-water bath. Then HATU (1524 mg, 4.01 mmol)
was added while cooling was continued. The reaction mixture was
stirred at 0.degree. C. for 30 minutes and allowed to reach room
temperature for 1 h. The reaction mixture was loaded on a column
and purified using silica gel column chromatography (ethyl acetate
in heptane form 0 to 100%) to afford methyl (2 S,3
S)-2-methyl-142-oxo-2-
[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetyl]pyrrolidine-3-carboxyl-
ate (1000 mg) as colorless oil. Method D, Rt=1.59 min., m/z=309.3
(M-H).sup.-, Exact mass: 310.1.
[0203] Methyl
(2S,3S)-2-methyl-142-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]ac-
etyl]-pyrrolidine-3-carboxylate (400 mg, 1.29 mmol) was stirred in
methanol (10 mL) at room temperature. To this was added NaOH (1M in
H.sub.2O) (1.35 mL, 1 M, 1.35 mmol) drop wise and the mixture was
stirred for 20 hours. After 20 hours more NaOH (1M in H.sub.2O)
(0.26 mL, 1 M, 0.26 mmol) was added to the reaction mixture which
was stirred at room temperature for 2 hours.The reaction was
quenched with HCl (1M in H.sub.2O) (1.61 mL, 1 M, 1.61 mmol) and
concentrated to keep 3 mL residue. The residue was extracted with
2-methyl THF (2.times.20 mL). The combined organic layers were
dried (Na.sub.2SO.sub.4) and evaporated to dryness to afford
(2S,3S)-2-methyl-1-[2-oxo-2-
[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]
acetyl]pyrrolidine-3-carboxylic acid (440 mg) as white solid after
standing.
[0204] A solution of (2 S,3 S)-2-methyl-142-oxo-2-
[[(1R)-2,2,2-trifluoro-l-methyl-ethyl]
amino]-acetyl]pyrrolidine-3-carboxylic acid (190 mg, 0.64 mmol) in
DMF (2 mL) and 3-chloro-4,5-difluoroaniline (115.4 mg, 0.71 mmol)
was cooled to 0.degree. C. in an ice-water bath. Then HATU (292.6
mg, 0.77 mmol) was added, while cooling was continued. The reaction
mixture was stirred at 0.degree. C. for 30 minutes and allowed to
reach room temperature for 24 h. The reaction mixture was loaded on
a column and purified using silica gel column chromatography (ethyl
acetate in heptane form 0 to 100%) and further via preparative HPLC
(Stationary phase: RP) (Bridge Prep C18 OBD-10.mu.m,30.times.150mm,
Mobile phase: 0.25% NH.sub.4HCO.sub.3 solution in water,
CH.sub.3CN) resulting in compound 33a (40 mg) and compound 33b (33
mg). 33a:
(2S,3R)--N--(3-chloro-4,5-difluoro-phenyl)-2-methyl-1-[2-oxo-2-[[(1R)-2,2-
,2-trifluoro-1-methyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide
Method B, Rt=1.06 min., m/z=440.1 (M-H).sup.-, Exact mass: 441.1.
33b:
(2S,3S)--N--(3-chloro-4,5-difluoro-phenyl)-2-methyl-142-oxo-2-[[(1R)-62,2-
,2-trifluoro-1-methyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide.Method
B, Rt=1.11 min., m/z=440.1 (M-H).sup.-, Exact mass: 441.1. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 0.99-1.05 (m, 3 H),
1.26-1.34 (m, 3 H), 1.95-2.06 (m, 1 H), 2.23-2.39 (m, 1 H),
3.11-3.27 (m, 1 H), 3.38-3.84 (m, 2 H), 4.46-4.87 (m, 2 H),
7.60-7.69 (m, 2 H), 9.17-9.43 (m, 1 H), 10.24-10.51 (m, 1 H) as a
mixture of rotamers
Compound 34: (2
S)-2-methyl-142-oxo-2-[[(1R)-2,2,2-trifluoro-l-methyl-ethyl]
amino]acetyl]-N-(3,4,5-trifluorophenyl)pyrrolidine-3-carboxamide
##STR00053##
[0206] Compound 34a (44 mg) and 34b (52 mg) were prepared similarly
as described for compound 33a and 33 b, using
3,4,5-trifluoroaniline instead of 3-chloro-4,5-difluoroaniline.
34a:
(2S,3R)-2-methyl-1-[2-oxo-2-[[(1R)-2,2,2-trifluoro-l-methyl-ethyl]amino]a-
cetyl]-N-(3,4,5-trifluorophenyl)pyrrolidine-3-carboxamide Method B,
Rt=1.02 min., m/z=424.1 (M-H)", Exact mass: 425.1. 34b:
(2S,3S)-2-methyl-l-[2-oxo-2-[[(1R)-2,2,2-trifluoro-l-methyl-ethyl]amino]a-
cetyl]-N-(3,4,5-trifluorophenyl)pyrrolidine-3-carboxamide Method B,
Rt=1.05 min., m/z=424.1 (M-H).sup.-, Exact mass: 425.1. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 0.99-1.05 (m, 3 H), 1.26-1.34
(m, 3 H), 1.92-2.07 (m, 1 H), 2.19-2.41 (m, 1 H), 3.08-3.28 (m, 1
H), 3.38-3.85 (m, 2 H), 4.45-4.87 (m, 2 H), 7.43-7.57 (m, 2 H),
9.30 (br. s., 1 H), 10.41 (br. s., 1 H) as a mixture of
rotamers.
Compound 35:
N-(3-chloro-2,4-difluoro-phenyl)-2-methyl-142-oxo-24((1R)-2,2,2-trifluoro-
-l-methyl-ethyl)amino]acetyl]piperidine-3-carboxamide
##STR00054##
[0208] Ethyl
1-(2-ethoxy-2-oxo-acetyl)-2-methyl-piperidine-3-carboxylate was
prepared from ethyl 2-methylpiperidine-3-carboxylate, similarly as
described for methyl
(2S,3S)-1-(2-ethoxy-2-oxo-acetyl)-2-methyl-pyrrolidine-3-carboxylate
from methyl (2S,3S)-2-methylpyrrolidine-3-carboxylate. Compound 35
was prepared similarly as described for compound 33, starting from
Ethyl 1-(2-ethoxy-2-oxo-acetyl)-2-methyl-piperidine-3-carboxylate
instead of methyl
(2S,3S)-1-(2-ethoxy-2-oxo-acetyl)-2-methyl-pyrrolidine-3-carboxyla-
te and using 3-chloro-2,4-difluoro-aniline instead of
3-chloro-4,5-difluoroaniline. Compound 35 (550 mg) was separated in
diastereoisomers 35a, 35b, 35c and 35d via Preparative SFC
(Stationary phase: Chiralpak Daicel IC 20.times.250 mm, Mobile
phase: CO.sub.2, EtOH with 0.2% iPrNH.sub.2). Compound 35a ((2S,3S)
or (2R,3R), first eluting on SFC, 70 mg), Method D, Rt=1.86 min.,
m/z=454.1 (M-H).sup.-, Exact mass: 455.1.Compound 35b ((2S,3S) or
(2R,3R), second eluting on SFC, 88 mg) Method D, Rt=1.87 min.,
m/z=454.1 (M-H).sup.-, Exact mass: 455.1. Compound 35c ((2S,3R) or
(2R,3S), third eluting on SFC, 86 mg), Method D, Rt=1.89 min.,
m/z=454.1 (M-H).sup.-, Exact mass: 455.1. Compound 35d ((2S,3R) or
(2R,3S), fourth eluting on SFC, 106 mg), Method D, Rt=1.88 min.,
m/z=454.1 (M-H).sup.-, Exact mass: 455.1.
[0209] Biological examples--anti-HBV activity of compounds of
formula (I)
[0210] The anti-HBV activity was measured using a stable
transfected cell line, HepG2.2.15. This cell line was described to
secrete relatively consistent high levels of HBV virion particles,
which have been shown to cause both acute and chronic infection and
disease in chimpanzees. For the antiviral, assay cells were treated
twice for three days with serially diluted compound in 96-well
plates in duplicate. After 6 days of treatment the antiviral
activity was determined by quantification of purified HBV DNA from
secreted virions using realtime PCR and an HBV specific primer set
and probe.
[0211] The anti HBV activity was also measured using the HepG2.117
cell line, a stable, inducibly HBV producing cell line, which
replicates HBV in the absence of doxicycline (Tet-off system). For
the antiviral assay, HBV replication was induced, followed by a
treatment with serially diluted compound in 96-well plates in
duplicate. After 3 days of treatment, the antiviral activity was
determined by quantification of intracellular HBV DNA using
realtime PCR and an HBV specific primer set and probe.
[0212] Cytotoxicity of the compounds was tested using HepG2 cells,
incubated for 4 days in the presence of compounds. The viability of
the cells was assessed using a Resazurin assay. Results are
displayed in Table 1.
TABLE-US-00003 TABLE 1 HepG2 HepG2 HepG2 Co. 2.15 117 4 days No.
EC50 (.mu.M) EC50 (.mu.M) CC50 (.mu.M) 1 0.020 0.018 >25 2 0.070
0.033 >25 3 0.141 0.026 >25 4 0.126 0.071 >25 5 0.112
0.046 >25 6 0.301 0.257 >25 7 0.067 0.117 >25 8 0.065
0.038 >25 9 0.120 0.134 >25 10 0.008 0.009 >25 11 0.032
0.017 >25 12 0.321 0.115 >25 13 0.020 0.035 >25 14 0.064
0.045 >25 15 0.025 0.047 >25 16 0.058 0.035 >25 17a >1
>1 >25 17b 0.918 0.796 >25 17c >1 >1 >25 17d
0.070 0.032 >25 18 0.670 >25 19 0.496 0.449 >25 20 0.289
0.645 >25 21 0.063 0.063 >25 22 0.110 0.128 >25 23 0.380
0.575 >25 24 0.134 0.384 >25 25 0.042 0.031 >25 26 0.168
0.122 >25 27 0.119 0.126 >25 28 0.050 0.083 >25 29a 0.010
0.011 >25 29b >1 >1 >25 29 0.018 0.048 >25 30 0.161
0.125 >25 31 0.134 0.143 >25 32 0.052 >25 33a >0.5
>25 33b 0.005 >25 34a >0.5 >25 34b 0.004 >25 35a
>1 >1 >25 35b 0.195 0.483 >25 35c >1 >1 >25
35d >1 >1 >25
* * * * *